• New production technologies give back to the traditional diet.
• Along with the defense of the natural products themselves of this diet has preserved the ways of preparation (recipes and techniques), as an expression of culture.
• Globalization and economic development have affected the pattern of diet in the Mediterranean basin have been modified and some health indicators for which it was associated.
"Modernity has endangered the traditional Mediterranean diet." The phrase is striking Majem Lluis Serra, President of the Mediterranean Diet Foundation and warning about the effects of technology on traditional diets. A specialist's view "there are no insurmountable contradictions between new technologies and traditional food but it is necessary to enable the appropriate formulas to make the tradition persists, both from the health point of view and from a cultural consideration."
Following this discussion, put on the table during the VIII National Congress of Community Nutrition, Lluis Serra announced a series of initiatives in order to protect an ancient formula feeding. Among them the decision coordinated from Spain, Italy, Greece and Morocco to apply to UNESCO for consideration of the Mediterranean diet as a World Heritage Site.
Lluis Serra believes that "in many cases traditional foods are better quality than the new ones. From this point of view, "analyzes the expert," it is interesting to use new technologies to improve manufacturing processes of traditional products such as bread and yoghurt. It is introduced into the food chain classic products that are possible with the greatest similarity craftsmanship. It is necessary to make the technology feel the tradition. "
Believes the president of the Foundation Mediterranean Diet "in the industry today only partially addresses this issue. We use the term "Mediterranean" without necessarily keep all its nutritional values. They have many years of effort to achieve the identification of the Mediterranean diet as a powerful nutritional value and quality to that now used by some evil. "
The specialist suspected that "the Mediterranean diet is in danger of absorption by other food industry. It is not just to preserve a set of specific foods, but a whole range of recipes that make up the cultural heritage of a people. "
The term reflects the Mediterranean diet, dietary pattern characteristic of several countries of the Mediterranean basin in the 1960s was associated with increased longevity and reduced morbidity due to certain chronic diseases. It is characterized by an abundant intake of fruits, vegetables, bread and other cereals, pulses and nuts, fresh produce from the garden, seasonal and minimally processed, with a typical sweet desserts based on nuts, olive oil and sweet honey consumed during the holidays, olive oil as the main source of fat, dairy products (cheese and yogurt) are consumed in moderation, less than four eggs a week, red meat consumed occasionally and in small quantities and wine, with consumption slight to moderate, especially during meals.
It is clear that since 1960, globalization, economic development, etc.. have affected the pattern of diet in the Mediterranean basin have been modified and some health indicators for which it was associated. The finding led to these changes, in 2002, has organized an international working group in the Scientific Park of Barcelona under the auspices of the Mediterranean Diet Foundation, intended to analyze the situation where the diet was Mediterranean and the needs of its redefinition.
The working group expressed the need to update the dietary guidelines according to scientific evidence. For example, evidence of the need for integrated products involves a review of the recommendations regarding the consumption of pasta and bread. It should be noted, moreover, the whole concept of Mediterranean diet, promoting other aspects of it as exercise or enjoy a meal and the desktop.
Similarly, the findings work in the development of qualitative and positive, emphasizing not so much what foods should be restricted only to consume what others have, and to quantify intake. For those groups of foods such as fruits and vegetables, in which there is no evidence of excessive contraindications, should be cited only minimal intakes, in contrast to other foods would be more appropriate to set the maximum recommended.
Similarly recommended rethinking the pyramid model as a visual guide food. The basket is a very familiar figure in the Mediterranean countries and would replace the traditional pyramid, and to assess the changes that have occurred in the Mediterranean diet, especially in the Mediterranean countries of Europe.
There is also the proposal to assess the impact that the incorporation of novel foods and their preparation has been in the Mediterranean diet, to distinguish the typical Mediterranean diet and daily consumer products reserved for the holidays, do not promote only the dietary pattern but also the lifestyle of the Mediterranean diet, culture and good living and allow the incorporation of new products from the current exchange of cultures without it there is a deterioration in the quality of the Mediterranean diet.
Sunday, February 15, 2009
The SEOM rewards responsible and positive information about cancer.
Delivery of the VI SEOM Journalism Award, call for the seventh edition.
• Ainhoa Iriberri of Public Health of Time Canal Nou has been the winners of the VI edition
• The award coincides with the celebration of the Congress SEOM Continuum of Care in Medical Oncology
The Spanish Society of Medical Oncology (SEOM) has announced the winners of the sixth edition of the Prize for Journalism organized in collaboration with the National Association of Health data (ANIS) in the III Congress SEOM Continuum of Care in Oncology Medicine being held on 23 and 24 October 2008 in Palma de Mallorca.
Ainhoa Iriberri journalist specializing in health, has proven successful in the written press category for his article "When the cure for cancer" published in the December 14, 2007.
For its part, Time Health program, produced by the producer valenciana ACCA MEDIA, received the award in the category of audiovisual media for his monograph on breast cancer, delivered on December 27, 2007 in Valencia TV Canal Nou .
In both cases the jury has highlighted the quality of information and rigorous treatment of the news.
"When cancer cure" is a story that made Ainhoa Iriberri on childhood cancer, a type of cancer in their lines as written "struck in 2006 to 898 families."
"I am delighted to receive this award, commented Ainhora Iriberri because, apart from personal satisfaction, is an appreciation for the science section of a new journal, Public wager that with determination, with six pages a day, for an information considered minor for other means. "
The journalist wanted to emphasize that public "is very important to get away from the alarmism and pessimism when it comes to reporting on cancer because it is safer that among your readers, whether a patient or a relative of a cancer patient. This does not mean they tell the news about this disease but, in my opinion, it is very important that you contextualizes the expert. The SEOM, as evidenced by the call of the Journalism Prize, takes seriously the work and there is always a member of its board prepared to meet the press, albeit at times impossible to handle the journalists. "
Time Morning Salut is a 40-minute daily broadcast, live and in Valencia in Canal Nou. Develops as a doctor in a way that is entertaining and educational emphasis on promoting healthy habits for the prevention of major diseases affecting the population, including breast cancer. The program is consolidated into a grid and is led by Dr. José María Masip and counts each day with the help of leading medical professionals in the Valencian Community that explain the advances in diagnosis and treatment of individual diseases treated.
Miguel Angel Tobias, director and executive producer of ACCA MEDIA ENTERPRISE time and therefore of Health, said at the prize that "we are very happy and excited with this award. We are a recognition of work done over 70 people every day with great enthusiasm. Of course, this award is for all of them. "
This time the program is entitled "Diagnostic techniques and treatment of breast cancer" and he stressed the importance of prevention in this disease. It was attended by Dr. Ana Lluch, Chief of Hematology and Medical Oncology at the Hospital Clínico Universitario de Valencia.
In the words of Time Salut "This program has sought to eliminate the fears that viewers may have the disease and to dispel the taboo that breast cancer is equal to a terminal illness. It comes to addressing breast cancer in a comprehensive and realistic, yet optimistic at a consultation in which we invite viewers to participate with questions on the street, and through the phone. "
The jury was composed by Dr. Ramon Colomer, president of SEOM, Dr. Antonio Duque, former president of SEOM, Dr. Maria Lopez, Scientific Secretary of SEOM; Jovell Albert, chairman of the Patients Forum, and Jose Manuel Gonzalez Bone, president and director of the ANIS Servimedia.
Similarly, it is called the Seventh Journalism Award SEOM in which jobs are valued especially those that contribute to the demystification of cancer as a terminal illness, to share the importance of prevention and publicize the work of oncology Spain. The prize is all the work published or broadcast during 2008. The basis of the Sixth Prize is available at the website: www.seom.org
The words of Dr. Colomer in the event clearly shows the spirit of this award "The fight against cancer requires a good level of information. Since SEOM encourage all professionals in the media to continue to participate with the same enthusiasm and excellence year after year and show us, who have not done so on previous occasions, the opportunity to present their stories Articles and features for this prize which has a clear track record of independence and pluralism. "
About the Spanish Society for Medical Oncology
The Spanish Society of Medical Oncology (SEOM) is a scientific, non-profit created to stimulate progress in scientific knowledge of cancer through the education and training of medical specialists in oncology and exchange with scientific purposes between national and foreign professionals.
At present, consists of over 1,000 members and is chaired by a renowned medical oncologist who change every 2 years to represent all the professionals with common interests in this area of healthcare.
One of the main purposes of the SEOM is to stimulate study and research of the disease and seek the approval criteria for clinical diagnosis and therapeutic treatment. To this end it proposes, among other things, promote the development of therapeutic means suitable to ensure coordination in these harmonious and complementary shade and encouraging consistency of approach for treating cancer in its various locations and extensions.
The SEOM is the view on the referent of Oncology in Spain, sailing from the Services for Medical Oncology is offered an excellent quality of care, encouraging the study and cancer research.
A scientific society is active and involved in information and training in Oncology at the different groups: medical, health administration, patients, general public, pharmaceutical industry and the media.
With regard to health education of Spanish society as it relates to cancer, SEOM is actively involved in preventing disease, promoting health initiatives and prevention outreach to the general population, and project funding directed research for cancer patients.
The SEOM considered essential to emphasize the importance of primary prevention of cancer with healthy life habits (avoiding obesity, smoking and sedentary lifestyle), vaccines, early diagnosis and the role of the Units of Genetic counseling can be help families with increased susceptibility to cancer.
Besides the Spanish Society of Medical Oncology has a strong social mission through participation in campaigns and dissemination of primary and secondary prevention aimed at the population and provides support to patients and their families.
• Ainhoa Iriberri of Public Health of Time Canal Nou has been the winners of the VI edition
• The award coincides with the celebration of the Congress SEOM Continuum of Care in Medical Oncology
The Spanish Society of Medical Oncology (SEOM) has announced the winners of the sixth edition of the Prize for Journalism organized in collaboration with the National Association of Health data (ANIS) in the III Congress SEOM Continuum of Care in Oncology Medicine being held on 23 and 24 October 2008 in Palma de Mallorca.
Ainhoa Iriberri journalist specializing in health, has proven successful in the written press category for his article "When the cure for cancer" published in the December 14, 2007.
For its part, Time Health program, produced by the producer valenciana ACCA MEDIA, received the award in the category of audiovisual media for his monograph on breast cancer, delivered on December 27, 2007 in Valencia TV Canal Nou .
In both cases the jury has highlighted the quality of information and rigorous treatment of the news.
"When cancer cure" is a story that made Ainhoa Iriberri on childhood cancer, a type of cancer in their lines as written "struck in 2006 to 898 families."
"I am delighted to receive this award, commented Ainhora Iriberri because, apart from personal satisfaction, is an appreciation for the science section of a new journal, Public wager that with determination, with six pages a day, for an information considered minor for other means. "
The journalist wanted to emphasize that public "is very important to get away from the alarmism and pessimism when it comes to reporting on cancer because it is safer that among your readers, whether a patient or a relative of a cancer patient. This does not mean they tell the news about this disease but, in my opinion, it is very important that you contextualizes the expert. The SEOM, as evidenced by the call of the Journalism Prize, takes seriously the work and there is always a member of its board prepared to meet the press, albeit at times impossible to handle the journalists. "
Time Morning Salut is a 40-minute daily broadcast, live and in Valencia in Canal Nou. Develops as a doctor in a way that is entertaining and educational emphasis on promoting healthy habits for the prevention of major diseases affecting the population, including breast cancer. The program is consolidated into a grid and is led by Dr. José María Masip and counts each day with the help of leading medical professionals in the Valencian Community that explain the advances in diagnosis and treatment of individual diseases treated.
Miguel Angel Tobias, director and executive producer of ACCA MEDIA ENTERPRISE time and therefore of Health, said at the prize that "we are very happy and excited with this award. We are a recognition of work done over 70 people every day with great enthusiasm. Of course, this award is for all of them. "
This time the program is entitled "Diagnostic techniques and treatment of breast cancer" and he stressed the importance of prevention in this disease. It was attended by Dr. Ana Lluch, Chief of Hematology and Medical Oncology at the Hospital Clínico Universitario de Valencia.
In the words of Time Salut "This program has sought to eliminate the fears that viewers may have the disease and to dispel the taboo that breast cancer is equal to a terminal illness. It comes to addressing breast cancer in a comprehensive and realistic, yet optimistic at a consultation in which we invite viewers to participate with questions on the street, and through the phone. "
The jury was composed by Dr. Ramon Colomer, president of SEOM, Dr. Antonio Duque, former president of SEOM, Dr. Maria Lopez, Scientific Secretary of SEOM; Jovell Albert, chairman of the Patients Forum, and Jose Manuel Gonzalez Bone, president and director of the ANIS Servimedia.
Similarly, it is called the Seventh Journalism Award SEOM in which jobs are valued especially those that contribute to the demystification of cancer as a terminal illness, to share the importance of prevention and publicize the work of oncology Spain. The prize is all the work published or broadcast during 2008. The basis of the Sixth Prize is available at the website: www.seom.org
The words of Dr. Colomer in the event clearly shows the spirit of this award "The fight against cancer requires a good level of information. Since SEOM encourage all professionals in the media to continue to participate with the same enthusiasm and excellence year after year and show us, who have not done so on previous occasions, the opportunity to present their stories Articles and features for this prize which has a clear track record of independence and pluralism. "
About the Spanish Society for Medical Oncology
The Spanish Society of Medical Oncology (SEOM) is a scientific, non-profit created to stimulate progress in scientific knowledge of cancer through the education and training of medical specialists in oncology and exchange with scientific purposes between national and foreign professionals.
At present, consists of over 1,000 members and is chaired by a renowned medical oncologist who change every 2 years to represent all the professionals with common interests in this area of healthcare.
One of the main purposes of the SEOM is to stimulate study and research of the disease and seek the approval criteria for clinical diagnosis and therapeutic treatment. To this end it proposes, among other things, promote the development of therapeutic means suitable to ensure coordination in these harmonious and complementary shade and encouraging consistency of approach for treating cancer in its various locations and extensions.
The SEOM is the view on the referent of Oncology in Spain, sailing from the Services for Medical Oncology is offered an excellent quality of care, encouraging the study and cancer research.
A scientific society is active and involved in information and training in Oncology at the different groups: medical, health administration, patients, general public, pharmaceutical industry and the media.
With regard to health education of Spanish society as it relates to cancer, SEOM is actively involved in preventing disease, promoting health initiatives and prevention outreach to the general population, and project funding directed research for cancer patients.
The SEOM considered essential to emphasize the importance of primary prevention of cancer with healthy life habits (avoiding obesity, smoking and sedentary lifestyle), vaccines, early diagnosis and the role of the Units of Genetic counseling can be help families with increased susceptibility to cancer.
Besides the Spanish Society of Medical Oncology has a strong social mission through participation in campaigns and dissemination of primary and secondary prevention aimed at the population and provides support to patients and their families.
Psychiatrists in Spain ADHD experts present new projects for the treatment of this disorder in children and adults.
Psychiatrists Spanish experts in ADHD (Hyperactivity Disorder and Attention Deficit) present new projects for the treatment of this disorder in children and adults
• The Central Nervous System Unit of the Spanish laboratory Juste organized a reunion with the best specialists in child psychiatry of the main national focal points (Fundación Hospital de Alcorcón Madrid, Hospital Clínico Universitario de Zaragoza, Hospital Clínico de Barcelona, University Hospital Vall d'Hebron ... to support new initiatives in dealing with patients suffering from ADHD and a new International Directory of research protocols and clinical treatment of this condition.
• Psychiatrists maintain that ADHD is a disease and clinical chemistry where there is a change in the production of neurotransmitters, primarily dopamine and noreadrenalina, and therefore should be treated pharmacologically and, subsequently, with a multidisciplinary psychological, psychoeducational and family to help patients who suffer from ADHD children and also adults.
• The child psychiatrists maintain that this disease affects between 8 and 10% of children and 5% of the adult population. However, only 1% of children are diagnosed and properly treated to improve their quality of life.
• These experts argue that many emerging Patients Associations in this condition because the Administration does not support or to patients or physicians. Proof of this is that there are no associations of patients with appendicitis, identifies these psychiatrists.
From left to right: Xavier Gastaminza, Psychiatrist, Hospital Universitario Vall d'Hebron; Ayats Arturo Perez, Director of the Division of Central Nervous System and Laboratory Juste Montañés Francisco, Chief of Psychiatry at the Hospital Fundación de Alcorcón, Madrid.
Unity of Central Nervous System Laboratory Spanish Juste has convened today in Madrid at the best experts in infant-juvenile psychiatry Spanish representatives of major hospitals in order to bring new and better treatment of and approach to the treatment of patients suffering Disorder and Attention Deficit Hyperactivity Disorder (ADHD) in children as in adults, affecting about 7% of children and 5% of the adult population according to WHO.
Among this panel highlights the presence of psychiatrists Alcorcón Hospital Foundation, the Hospital Clinic of Barcelona and the Hospital Universitario Vall d'Hebron.
According to these medical experts have stated, the average time it takes for a child to receive a correct diagnosis is too long and this disease is underdiagnosed in our country. "Specifically in Spain, it takes seven years to diagnose this disease compared to other European countries, eg UK, where it takes months to diagnose this disease," and adds, "only a further 1% of all Spanish population that suffers from this disorder is diagnosed and properly treated, "says Dr. Francisco Montañés, Chief of Psychiatry at the Hospital de Alcorcón.
These experts are calling for more aid and support from local authorities of each community and, especially, by the Ministry of Health. "Psychiatry is a specialty that has sufficient support from the government. ADHD is a disease that has a 80% inheritance. This means that the child psychiatric parents are trying to - adults with this disorder-and their children who also have this genetically inherited disease. This means that now we are without resources and totally collapsed in the treatment of this condition in Madrid, "says Dr. Francisco Montañés.
In fact, according to experts 50% of children with ADHD in the future will be people that if not properly treated will suffer from addictions to substances or have difficulties in their development work. "We found that 20% of adult patients who suffer from addictions to substances, really suffer with ADHD and a correct diagnosis can be solved his illness," says Dr. Montañés.
Dr. Xavier Gastaminza, Psychiatrist, Hospital Universitario Vall d'Hebron, supports these statements as more resources in infant-juvenile psychiatry can avoid spending a lot more in the future. "Patients Associations are emerging because we need help," says Xavier Gastaminza.
Due to the awareness that is having the knowledge of this disorder and there are websites like: http://www.hiperactividadmedicosypacientes.com "where patients' associations demanding more social support.
To respond to this social demand, the experts met today psychiatrists volunteered to perform various work projects. Have self GEITDAH acronyms mean Special Interest Group on ADHD. This panel aims to first, analyze all the international guidelines for diagnosis and treatment of this condition and subsequently made a guide for Spanish protocol, research and national treatment to serve as a reference for all of Europe.
Secondly, have been divided into two panels: the first group will analyze the results of drugs in the treatment of this condition and the second group of psychiatrists, analyze and report the findings of non-pharmacological treatments.
In this line psychiatrists agree that the methylphenidate extended release over 62 clinical trials worldwide has proved to be the best medicine star has appeared in these patients. "Spain has come a long way from the pharmacological point of view, as was recently launched Medikinet, a drug that takes effect during eight hours, the time for a fair day's work. There was a void in the market because until now the formulas and did indeed too long or too short time. Now we have formulas galenical balanced, "explains Dr. Montañés.
This group is coordinated by Dr. Francisco Montañes Rada, Head of Child Psychiatry and Dr. Xavier Alcorcón Gastaminza, Psychiatrist, Hospital Universitario Vall d'Hebron.
These experts want to share with the public that ADHD is a disease with a biochemical origin involvement in the production of the neurotransmitter dopamine and essentially noreadrenalina. Therefore, there must be a first time since a correct diagnosis is essential to treat patients pharmacologically to standardize the production of these neurotransmitters is a disorder in which dopamine and noreadrenalina.
In the words of Dr. Francis Montañés more than 70% of patients treated with Medikinet have seen a marked improvement of their symptoms and improved their quality of life. "The long-acting methylphenidate is a dopamine blocker," says Dr. Montañés.
These experts insist that once patients are treated pharmacologically and focused on, and require a multidisciplinary psychoeducational support and generally throughout society.
Other projects that have raised these specialists is to develop, with the sponsorship of the Central Nervous System Unit of the laboratory-Juste an International Guide for ADHD treatment, and developing software for patient records for future research projects ADHD and creating informative websites for physicians and specialists.
Moreover, these specialists will develop an existing project to classify various subtypes of ADHD creating. This requires that these distinctions are complex because the disease has a very important variable for the life of a patient and thus reach conclusions in advance of this disease. "The creation of sub-subtypes and variants in this disease is very complex and we need computers to share information to help children and adults suffering from this disease. This is another of our objectives, "says Dr. Xavier Gastaminza.
Dr. Francisco Mountains has indicated that it intends to conduct a registry of patients by subgroups within the ADHD alternative for care to meet the needs of these patients and improve drug treatments in fair measure to advance knowledge and to help improve their quality of life.
• The Central Nervous System Unit of the Spanish laboratory Juste organized a reunion with the best specialists in child psychiatry of the main national focal points (Fundación Hospital de Alcorcón Madrid, Hospital Clínico Universitario de Zaragoza, Hospital Clínico de Barcelona, University Hospital Vall d'Hebron ... to support new initiatives in dealing with patients suffering from ADHD and a new International Directory of research protocols and clinical treatment of this condition.
• Psychiatrists maintain that ADHD is a disease and clinical chemistry where there is a change in the production of neurotransmitters, primarily dopamine and noreadrenalina, and therefore should be treated pharmacologically and, subsequently, with a multidisciplinary psychological, psychoeducational and family to help patients who suffer from ADHD children and also adults.
• The child psychiatrists maintain that this disease affects between 8 and 10% of children and 5% of the adult population. However, only 1% of children are diagnosed and properly treated to improve their quality of life.
• These experts argue that many emerging Patients Associations in this condition because the Administration does not support or to patients or physicians. Proof of this is that there are no associations of patients with appendicitis, identifies these psychiatrists.
From left to right: Xavier Gastaminza, Psychiatrist, Hospital Universitario Vall d'Hebron; Ayats Arturo Perez, Director of the Division of Central Nervous System and Laboratory Juste Montañés Francisco, Chief of Psychiatry at the Hospital Fundación de Alcorcón, Madrid.
Unity of Central Nervous System Laboratory Spanish Juste has convened today in Madrid at the best experts in infant-juvenile psychiatry Spanish representatives of major hospitals in order to bring new and better treatment of and approach to the treatment of patients suffering Disorder and Attention Deficit Hyperactivity Disorder (ADHD) in children as in adults, affecting about 7% of children and 5% of the adult population according to WHO.
Among this panel highlights the presence of psychiatrists Alcorcón Hospital Foundation, the Hospital Clinic of Barcelona and the Hospital Universitario Vall d'Hebron.
According to these medical experts have stated, the average time it takes for a child to receive a correct diagnosis is too long and this disease is underdiagnosed in our country. "Specifically in Spain, it takes seven years to diagnose this disease compared to other European countries, eg UK, where it takes months to diagnose this disease," and adds, "only a further 1% of all Spanish population that suffers from this disorder is diagnosed and properly treated, "says Dr. Francisco Montañés, Chief of Psychiatry at the Hospital de Alcorcón.
These experts are calling for more aid and support from local authorities of each community and, especially, by the Ministry of Health. "Psychiatry is a specialty that has sufficient support from the government. ADHD is a disease that has a 80% inheritance. This means that the child psychiatric parents are trying to - adults with this disorder-and their children who also have this genetically inherited disease. This means that now we are without resources and totally collapsed in the treatment of this condition in Madrid, "says Dr. Francisco Montañés.
In fact, according to experts 50% of children with ADHD in the future will be people that if not properly treated will suffer from addictions to substances or have difficulties in their development work. "We found that 20% of adult patients who suffer from addictions to substances, really suffer with ADHD and a correct diagnosis can be solved his illness," says Dr. Montañés.
Dr. Xavier Gastaminza, Psychiatrist, Hospital Universitario Vall d'Hebron, supports these statements as more resources in infant-juvenile psychiatry can avoid spending a lot more in the future. "Patients Associations are emerging because we need help," says Xavier Gastaminza.
Due to the awareness that is having the knowledge of this disorder and there are websites like: http://www.hiperactividadmedicosypacientes.com "where patients' associations demanding more social support.
To respond to this social demand, the experts met today psychiatrists volunteered to perform various work projects. Have self GEITDAH acronyms mean Special Interest Group on ADHD. This panel aims to first, analyze all the international guidelines for diagnosis and treatment of this condition and subsequently made a guide for Spanish protocol, research and national treatment to serve as a reference for all of Europe.
Secondly, have been divided into two panels: the first group will analyze the results of drugs in the treatment of this condition and the second group of psychiatrists, analyze and report the findings of non-pharmacological treatments.
In this line psychiatrists agree that the methylphenidate extended release over 62 clinical trials worldwide has proved to be the best medicine star has appeared in these patients. "Spain has come a long way from the pharmacological point of view, as was recently launched Medikinet, a drug that takes effect during eight hours, the time for a fair day's work. There was a void in the market because until now the formulas and did indeed too long or too short time. Now we have formulas galenical balanced, "explains Dr. Montañés.
This group is coordinated by Dr. Francisco Montañes Rada, Head of Child Psychiatry and Dr. Xavier Alcorcón Gastaminza, Psychiatrist, Hospital Universitario Vall d'Hebron.
These experts want to share with the public that ADHD is a disease with a biochemical origin involvement in the production of the neurotransmitter dopamine and essentially noreadrenalina. Therefore, there must be a first time since a correct diagnosis is essential to treat patients pharmacologically to standardize the production of these neurotransmitters is a disorder in which dopamine and noreadrenalina.
In the words of Dr. Francis Montañés more than 70% of patients treated with Medikinet have seen a marked improvement of their symptoms and improved their quality of life. "The long-acting methylphenidate is a dopamine blocker," says Dr. Montañés.
These experts insist that once patients are treated pharmacologically and focused on, and require a multidisciplinary psychoeducational support and generally throughout society.
Other projects that have raised these specialists is to develop, with the sponsorship of the Central Nervous System Unit of the laboratory-Juste an International Guide for ADHD treatment, and developing software for patient records for future research projects ADHD and creating informative websites for physicians and specialists.
Moreover, these specialists will develop an existing project to classify various subtypes of ADHD creating. This requires that these distinctions are complex because the disease has a very important variable for the life of a patient and thus reach conclusions in advance of this disease. "The creation of sub-subtypes and variants in this disease is very complex and we need computers to share information to help children and adults suffering from this disease. This is another of our objectives, "says Dr. Xavier Gastaminza.
Dr. Francisco Mountains has indicated that it intends to conduct a registry of patients by subgroups within the ADHD alternative for care to meet the needs of these patients and improve drug treatments in fair measure to advance knowledge and to help improve their quality of life.
Saturday, February 14, 2009
www.hiperactividadmedicosypacientes.com a new form of communication between patients with ADHD, patients' associations, doctors and teachers.
- This portal will be a meeting point for professionals and patients. It advocates the participation of associations and foundations that cater to patients who suffer from ADHD (Disorder and Attention Deficit Hyperactivity Disorder) which affects up to 10% of children and adults, according to WHO.
- Associations and Foundations of ADHD claim through this site to offer financial assistance programs that improve the quality of life of these patients and reveal their problems to get funds. Say they need more financial aid to help the sick and less electoral opportunism.
- This site was created as a new communication channel with two fundamental objectives. First, improve the quality of life of people suffering from ADHD, and secondly, to unify the views of all the specialists, doctors, teachers and families.
- Account in drafting the voluntary collaboration of six pediatric neurologist and psychiatrists nationally and internationally.
Ignorance of the Disorder and Attention Deficit Hyperactivity Disorder (ADHD) and the lack of information on the latest treatments to improve their symptoms are the first problems faced by patients suffering from this condition which is between 7 and 10% of children and, similarly, to adults, says the WHO, World Health Organization.
With the intention to meet this demand for information from ADHD, has just launched the so-called Web www.hiperactividadmedicosypacientes.com, intended as a meeting point between medical specialists and psychiatrists pediatric neurologist, Associations and Foundations of Patients and teachers .
Since December, the Web will offer the latest news and all the latest news on ADHD emphasizing the important role being undertaken by the Associations and Foundations of patients to achieve new advances in treatments of this disease. Also, this site will facilitate the participation of patients through the different sections with interviews, news, features and articles. The contents will be fully open.
From the editors of this web site explains that this website has several sections: "News", which addresses a summary of the most outstanding news, "Curiosities," which tracks small attempt to help families and teachers to be alert. Remains the "Our Voices", which is an exclusive section for Associations and Foundations, where they presented their progress and news. Then the "names" that reflects the real first-person testimony of a family or a hyperactive adult. Noteworthy is the section "News" section led by an international scientific team of medical specialists in which they present the latest international scientific developments in the treatment of this condition.
In the drafting of all sections of the writing team of this website is the opinion of the prestigious medical specialists who are currently leading in the treatment of this pathology in both Spain and USA. Emphasizes the participation of Dr. Agustin Legido, Chief neuropediatrics Christopher's Hospital for Children's Hospital of Philadelphia and Dr. Alvaro Pascual Leone, Professor of Neurology at Harvard Medical School.
In addition, this Web collaborate in five medical specialists who wanted to support this initiative on a voluntary and non-profit, for example, Dr. Fernando Mulas, Chief neuropediatrics Fe Hospital in Valencia and the Valencian Institute of Pediatric Neurology Invanep, Dr. Francisco Montanes, Head of the Psychiatric Hospital of Madrid Alcorcon Foundation, Dr. Julian Vaquerizo, Head of Badajoz neuropediatrics's Hospital pediatric neurologist and Alberto Fernández Jaén. Those three were joined by specialists.
● Nexo doctor: A Scientific Committee where pediatric neurologist and psychiatrists are in agreement
Each of the doctors and their skills have been shared. Dr. Agustin Legido provide vision and the application of the latest ADHD treatment in American hospitals and clinics. The Doctor says that "the most remarkable of this website is to combine approaches in diagnosis and treatment from psychiatrists, pediatric neurologist, and all the specialists involved in treating this disease. We will work together with one common goal: Improving the quality of life of these patients. Doctor says Legido.
Dr. Fernando Mulas is emphatic "We implemented a Web short and readable text that allows us to create a relationship between patients and doctors" - and says "This site represents an interactive practical link between the medical profession. Our mission is to serve society, "says the pediatric neurologist.
● Patients Associations and alleged election promises. No longer will we be silent
For its part, the associations of ADHD patients are not left behind. Bet on the development of these initiatives in the multidisciplinary teams involved, and expressing that ADHD requires a plural.
"On this site we are all in the same boat: psychologists, teachers, physicians, patient associations and foundations, which is a guarantee of success," said Elena Fernandez, President of Fundaicyl, the Foundation for Aid to Children Castilla-Leon.
María Jesús Torres, President of the Association of Pamplona, takes the same view and further adds that they need more practical experiences. "We have called for more tests and specific activities of self-esteem, sensory stimulation. So far, everything we see on the part of specialists is very theoretical. In our country, it takes seven years to children in diagnosing this disease compared to one year in the UK With these differences ... I wonder what is happening in Geriatrics or chronically ill, "recalls the president of the Association of Patients Pamplona
Elena Fernandez is resounding "We have promised a lot. We face a political and social problem. We want this site to reflect our reality the political sector. "The I'll then come." We promise things then do not comply, "added the Director of Fundaicyl.
In his view, the PP is ahead in this area, because this group has just submitted a proposal through a motion calling on the Government to take necessary measures to facilitate early diagnosis and treatment of persons presenting ADHD. "But we all know that politicians make promises and then desdicen with great ease. The sick is not played to win an election. When the elections are approaching and we promise to support, say they earn when they have no budget ... I wonder: What car is it? "Added the Director of Fundaicyl.
● Teachers full support to the Patients Associations
Has finished placing the child with ADHD in the last row because it bothers others. Phrases like "Take her to the school. Do not wait, "should disappear.
Opens this section because evidence in this edition of Web-received many requests from many teachers who have expressed a special interest in helping develop the skills and qualities of people who suffer from ADHD.
"In our local music schools, we have found that adults and children with ADHD, if properly stimulated and motivated, are capable of excellent creative work. His creativity in certain areas is well above average, "says Manuela Ruiz, a piano teacher with over 30 years of experience nationally and internationally.
Correct to state that shares Dr. Luis Rojas Marcos, Professor in Psychiatry and author of numerous works hyperactive states. This specialist explained that, in your case, with the support of their teachers who invested in enhancing their musical qualities. "With ten years of age, passed from a burning forest, with the resulting penalty, the civil guard to play the drums and piano. My teachers helped me develop my talent and the music helped me positivized my weaknesses, "says Professor Marcos Rojas, a father of four children - one with ADHD.
2 out of 10 Spaniards are using new technology to learn about neurological disorders.
• It is the main result of the study by the SEN in 2008, which contrasts with the previous survey in 2005 that the Internet was consulted by only 9% of the Spanish population
• The survey confirms a double trend: the emergence of new technologies in the field of health information and the importance that society gives to education and information on health issues
• Therefore, the Spanish Society of Neurology bet on digital media and communication as a tool for all public know first hand these diseases and improve their prevention and treatment and eliminate the stigma experienced by patients
• Only 18% of Canadian respondents said they had gone to a neurologist throughout his life despite the high prevalence of neurological disorders. Stroke, for example, is the leading cause of death among women in our country
In pursuance of the objectives of the Spanish Society of Neurology to spread awareness of neurological diseases and neuroscience, has a population survey conducted shows that the fact that "2 out of 10 Spaniards who participated in the study identified the Internet as means to search for information on neurological diseases. " And although the percentage is 70% far he go to a family doctor for information, the double trend which has been observed in recent times is the emergence of new technologies in the field of health information and the importance that society gives to education and information on health topics.
Furthermore, according to the survey of SEN, only 18% of respondents said they had gone to a neurologist throughout his life. And among those who reported having visited a neurologist at some time, 33% report having made the visit less than 1 year, followed by 28% who indicated having visited the neurologist "for over 5 years." These data contrast, however, with the trend in the incidence and importance of neurological diseases have had in recent years. According to the impact of social and neurological diseases in Spain, the Fund. Spanish Neurological Disease, it is estimated that between 6 and 7.5 million people suffer from a neurological disease, and is a factor that grows each year due to an aging population and increased life expectancy by reducing mortality other diseases.
The poll, conducted for SEN by the Research Institute in 2008, aims at determining the degree of knowledge that society has about neurological diseases, conferred upon him the severity, how often they visit rioja andalusia neurologist or specialist who wait among other things. The aim of the SEN is also able to compare data from this survey with in 2005 to determine whether the changes that are experienced in the perception of society are at the same rate as the incidence and evolution of disease neurological.
To present the findings of the survey chose the SEN framework of its 60th Annual Meeting, considered the most important forum for the Society promotes the dissemination of key developments and progress in the field of neurology. Below are the results of the study in relation to different variables:
Person or means of obtaining information about neurological diseases
The highlight here is the emergence of the internet as a half to find information on neurological diseases, as compared to the survey by the SEN in the year 2005, this item appeared in 9%. Three years ago, the doctor was the first source in 77% of cases, highlighting the primary care and family-only 6% of respondents.
2008 survey data .-
• Although the doctor stresses (mainly the family) as the person that would be used primarily to report certain neurological diseases (including 7 out of 10 interviewees mentioned the figure of the doctor), the Internet has broken so reaching the level of 23%. He continues, although by far the relatives (6%) as the person or means of obtaining information about neurological disorders.
• For ages, the proportion using the internet has risen among young people. Specifically 35% of respondents between 18 and 24 years as highlighted as a potential means of information.
• Stresses are so significant that people in the Northwest and the East in a percentage greater than 80% decided to go to the doctor for information.
• Family members receive a greater number of mentions among the residents of the North (23%) compared with other regions of Spain.
• Among different doctors cited clearly states the doctor followed by the neurologist. Likewise, among the Internet highlight Google as the main vehicle for finding information, and among family members are named in a greater degree cousins and brothers.
Frequency of visits to the Neurologist
Variable in this study, it is important to note the low percentage of visits to the neurologist, since only 18% of respondents claim to have visited the Neurologist's ever in your life. This percentage is significantly higher visitation in men (22% vs. 14%). Similarly, the percentage of visits was higher among young people aged 18-24 (25%), and data that contradicts the widespread perception that neurological diseases are unique to the "elderly" - and those between 55-64 years (22%), those of lower middle class / low (21%) and residents of the Northeast (25%) and South (25%).
This contrasts, however, the fact that neurological diseases have increased in incidence and importance. Cerebrovascular disease incidence has increased in recent times due to the aging of the population: if in 2003 the prevalence of stroke in patients older than 65 years was 7.5%, indicating the expectation that 2030 will be 742,500 patients in Spain and 2050 would be 1,129,000, according to the latest report from the Spanish Foundation for Neurologic Diseases (FEEN).
2008 survey data .-
• Among those who indicated having visited the Neurologist on occasion, 33% report having made the visit less than 1 years and they are followed by those who claim to have made the visit for over 5 years (28%).
• They come to be people between 35-44 years who have most recently visited the neurologist, as well as those of middle and middle class residents in the East (56%).
• On the lower frequency of visits, it stands out among people 45-54 years (60%) and inhabitants of the South (35%.
• The main reason for the visit to the Neurologist consultation relates to the treatment of headache (19%), followed by migraine (17%).
• Are people from 55 to 64 years in which a higher percentage of subjects attending Headache (46%) and migraine (36%). Also, the headaches have a greater impact in the Northeast (27%) and Northwest (29%), while migraines are mentioned more in the center (31%).
• The main route by which it reaches the Neurologist is through the GP, as indicated by half of people who claim to have seen the neurologist. This was followed by the respondent's own decision to go to consultation (15%) and because they come from prescribed emergencies (14%).
• Access from the GP has the greatest effect among those respondents aged 55-64 (73%) residents in the South Peninsula (70%) and those of upper class / upper middle (67%).
• It is among the inhabitants of the Northeast where his own decision to visit a Neurologist is strongest (27% recall).
Awareness of disease
This variable, called attention to change considerably to knowledge of neurological diseases has been experienced among respondents with regard to the latest survey conducted by the SEN in the year 2005. Currently, Alzheimer's and Parkinson are among the five best-known diseases while in 2005 only came with Alzheimer's disease such as cancer or depression.
2008 survey data .-
• Among the most famous include the Cancer and Alzheimer's disease, where 95% and 94% respectively demonstrate their knowledge of these diseases. A follow them notoriety as a percentage of depression (93% of knowledge), osteoarthritis (91%) and Parkinson (90%).
• When considering only the degree of awareness of neurological diseases, Alzheimer's disease becomes better known (94%), followed by Parkinson (90%) and migraine (87%).
• Although cancer is the most well known disease, by age group highlights that in the groups 35-44 years and 55-64 years of Alzheimer's has greater knowledge, even beyond the cancer and even in this last group Depression of 55-65 to be the best known disease.
Specialist to be used for that type of disease
This section is where you can see one of the most notable changes with respect to the 2005 survey. At that time, only 16% of respondents come from a neurologist to treat diseases such as multiple sclerosis and even surprising answers as to 39% would turn to to deal with this trauma disorder of the nervous system directly and 38% do not know what kind consult. Currently, in the 2008 survey, participants referred to the neurologist have all those diseases of neuronal character. This was followed in the family doctor endorsements.
2008 survey data .-
• Based on all those who have referred to a specialist neurologist who would resort to any of the mentioned types of disease, it is clear that Alzheimer's is where more people would turn from a neurologist (68%), followed by Parkinson ( 58%) and migraine (55%).
• Among the neurological diseases, the MS would be one in which there is less association with the figure of the neurologist, and we find that only 30% would come from a neurologist.
Consideration of the level of severity of neurological disease
In the earlier study, the neurological disease is more serious consideration for respondents was multiple sclerosis, although not known to the specialist who treated with a level of severity of 6.6 on 7 (very severe), almost equal to the severity of the cancer. The new data show that stroke, which is currently the leading cause of death among women, has become the neurological disorder is considered more serious.
2008 survey data .-
• Cancer is a disease considered to be more serious, with an average severity of 6.62 points on a scale from 1 (nothing serious) to 7 (very severe).
• When Cancer is still the level of seriousness with a stroke average of 6.48 and 6.42 of an Alzheimer half seriously.
• Migraines (4.72) and headaches (4.47) are less serious in those types of opinions the interviewees.
• Considering only the nature of neurological diseases, stroke, as discussed above, is considered to be the most serious disease, followed by Alzheimer (6.42 seriousness about 7 points), the MS (6.32) and dementia (6.01 ).
• Although there are no significant differences, it is seen that stroke has a greater impact on severity among women (6.53), those aged 18-24 (6.60), the middle class and low-low (6.60 ) and residents in the South (6.57).
VARIABLES TO HIGHLIGHT
Ratings Neurólogo Vs Other Specialties
• In assessing the specialty of Neurólogo, almost half of those aware of the existence of that particular value as excellent or very good, that percentage rises to 64% if one considers also those that give a good assessment. On a scale of 1-7, the average value is about 5.70 points.
• Only 4% rate the specialty of Neurology as bad or very bad.
• When positioning andalusia Neurólogo compared to others, it would occupy the second position value (average of 5.70 points out of 7) below the trauma (average 5.72) and above other specialists such as the oncologist, ophthalmologist, gynecologist etc..
• Although there are no significant differences, it is women who give an average higher than for men (5.74 to 5.65 for men) and those with 55 and 64 years (5.72).
• In class, out of the middle class and low-low as those that give a higher rating (5.95). They are residents in the Northeast (6.12), South (5.93) and Central (5.80) which have a view of the most valued Neurólogo compared to Northern (4.35).
Expectations and Assessment of Neurologist
• Among the different aspects that are expected to accomplish in the course of visiting the neurologist, include the proper treatment (37% of mentions), followed by the solution to problems (30%) and do everything possible to heal andalusia sick (22%).
• Regarding the priority areas worth a visit to the neurologist, two stand above the rest like the fact that Neurólogo relieve the symptoms of the disease and help prevent disease, both with 27% recall.
Awareness of Neurology
• When asked about the degree of knowledge about the specialty of neurology, 28% of spontaneously mentioned, that percentage rises to 69% when it is suggested that specialty, positioning itself as the first known specialty suggested above other specialties such as rheumatology, gynecology, oncology, etc..
• Considering the total number of mentions (spontaneous + suggested), neurology represents the second most famous specialty of cardiology behind, namely the 82% refers to the specialty of Neurology.
• They come to be aged between 18 and 24 years (87%) and those 35-44 years (87%) which have greater visibility of the specialty of Neurology. Similarly, it is the residents in the East (85%) and South Peninsula (90%) who have greater knowledge.
Source information neurologist and / or neurological diseases
• The principal means by which it is aware of the figure of the neurologist and / or neurological diseases is represented by the family, mentioned in 50% of cases. Followed by information obtained through the doctor (18%) and television, with 15% recall.
• women who are at a significantly higher percentage of men to have consistency across the family (56% vs. 45%). They are people between 25-34 years (57%) and residents of the Northwest (62%) who have also learned through the family.
• The doctor is strongest among young people aged 18-24 (31%) and inhabitants of the North (34%) and television among those 45-54 and 65 and over (19%) and inhabitants of Central and Northeast (19%).
• For that point the doctor as a vehicle of information, names the doctor, followed by the neurologist and specialist in general.
TECHNICAL SURVEY
• Universe: Men and women 18 and older.
• Scope: National level by Nielsen Region (Northwest, Northeast, North, Central, South and East) and habitat size (up to 50,000 inhab. / / 50.001-200.000 / / 200.001-500.000 / / more than 200,000)
• Camp dates: June 2008.
• Sample size: 400n. Interview: Telephonic by CATI system (Computer Assisted Personal Interview
• Sampling: Random stratified multistage Nielsen region, province and size of habitat, by telephone households and individuals by sex and age quotas.
• Responsible Institute: RESEARCH S.A. Member AEDEMO, ESOMAR, The Gallup Organization and received the International Code of Ethics ICC / ESOMAR Marketing and Social Research.
• The survey confirms a double trend: the emergence of new technologies in the field of health information and the importance that society gives to education and information on health issues
• Therefore, the Spanish Society of Neurology bet on digital media and communication as a tool for all public know first hand these diseases and improve their prevention and treatment and eliminate the stigma experienced by patients
• Only 18% of Canadian respondents said they had gone to a neurologist throughout his life despite the high prevalence of neurological disorders. Stroke, for example, is the leading cause of death among women in our country
In pursuance of the objectives of the Spanish Society of Neurology to spread awareness of neurological diseases and neuroscience, has a population survey conducted shows that the fact that "2 out of 10 Spaniards who participated in the study identified the Internet as means to search for information on neurological diseases. " And although the percentage is 70% far he go to a family doctor for information, the double trend which has been observed in recent times is the emergence of new technologies in the field of health information and the importance that society gives to education and information on health topics.
Furthermore, according to the survey of SEN, only 18% of respondents said they had gone to a neurologist throughout his life. And among those who reported having visited a neurologist at some time, 33% report having made the visit less than 1 year, followed by 28% who indicated having visited the neurologist "for over 5 years." These data contrast, however, with the trend in the incidence and importance of neurological diseases have had in recent years. According to the impact of social and neurological diseases in Spain, the Fund. Spanish Neurological Disease, it is estimated that between 6 and 7.5 million people suffer from a neurological disease, and is a factor that grows each year due to an aging population and increased life expectancy by reducing mortality other diseases.
The poll, conducted for SEN by the Research Institute in 2008, aims at determining the degree of knowledge that society has about neurological diseases, conferred upon him the severity, how often they visit rioja andalusia neurologist or specialist who wait among other things. The aim of the SEN is also able to compare data from this survey with in 2005 to determine whether the changes that are experienced in the perception of society are at the same rate as the incidence and evolution of disease neurological.
To present the findings of the survey chose the SEN framework of its 60th Annual Meeting, considered the most important forum for the Society promotes the dissemination of key developments and progress in the field of neurology. Below are the results of the study in relation to different variables:
Person or means of obtaining information about neurological diseases
The highlight here is the emergence of the internet as a half to find information on neurological diseases, as compared to the survey by the SEN in the year 2005, this item appeared in 9%. Three years ago, the doctor was the first source in 77% of cases, highlighting the primary care and family-only 6% of respondents.
2008 survey data .-
• Although the doctor stresses (mainly the family) as the person that would be used primarily to report certain neurological diseases (including 7 out of 10 interviewees mentioned the figure of the doctor), the Internet has broken so reaching the level of 23%. He continues, although by far the relatives (6%) as the person or means of obtaining information about neurological disorders.
• For ages, the proportion using the internet has risen among young people. Specifically 35% of respondents between 18 and 24 years as highlighted as a potential means of information.
• Stresses are so significant that people in the Northwest and the East in a percentage greater than 80% decided to go to the doctor for information.
• Family members receive a greater number of mentions among the residents of the North (23%) compared with other regions of Spain.
• Among different doctors cited clearly states the doctor followed by the neurologist. Likewise, among the Internet highlight Google as the main vehicle for finding information, and among family members are named in a greater degree cousins and brothers.
Frequency of visits to the Neurologist
Variable in this study, it is important to note the low percentage of visits to the neurologist, since only 18% of respondents claim to have visited the Neurologist's ever in your life. This percentage is significantly higher visitation in men (22% vs. 14%). Similarly, the percentage of visits was higher among young people aged 18-24 (25%), and data that contradicts the widespread perception that neurological diseases are unique to the "elderly" - and those between 55-64 years (22%), those of lower middle class / low (21%) and residents of the Northeast (25%) and South (25%).
This contrasts, however, the fact that neurological diseases have increased in incidence and importance. Cerebrovascular disease incidence has increased in recent times due to the aging of the population: if in 2003 the prevalence of stroke in patients older than 65 years was 7.5%, indicating the expectation that 2030 will be 742,500 patients in Spain and 2050 would be 1,129,000, according to the latest report from the Spanish Foundation for Neurologic Diseases (FEEN).
2008 survey data .-
• Among those who indicated having visited the Neurologist on occasion, 33% report having made the visit less than 1 years and they are followed by those who claim to have made the visit for over 5 years (28%).
• They come to be people between 35-44 years who have most recently visited the neurologist, as well as those of middle and middle class residents in the East (56%).
• On the lower frequency of visits, it stands out among people 45-54 years (60%) and inhabitants of the South (35%.
• The main reason for the visit to the Neurologist consultation relates to the treatment of headache (19%), followed by migraine (17%).
• Are people from 55 to 64 years in which a higher percentage of subjects attending Headache (46%) and migraine (36%). Also, the headaches have a greater impact in the Northeast (27%) and Northwest (29%), while migraines are mentioned more in the center (31%).
• The main route by which it reaches the Neurologist is through the GP, as indicated by half of people who claim to have seen the neurologist. This was followed by the respondent's own decision to go to consultation (15%) and because they come from prescribed emergencies (14%).
• Access from the GP has the greatest effect among those respondents aged 55-64 (73%) residents in the South Peninsula (70%) and those of upper class / upper middle (67%).
• It is among the inhabitants of the Northeast where his own decision to visit a Neurologist is strongest (27% recall).
Awareness of disease
This variable, called attention to change considerably to knowledge of neurological diseases has been experienced among respondents with regard to the latest survey conducted by the SEN in the year 2005. Currently, Alzheimer's and Parkinson are among the five best-known diseases while in 2005 only came with Alzheimer's disease such as cancer or depression.
2008 survey data .-
• Among the most famous include the Cancer and Alzheimer's disease, where 95% and 94% respectively demonstrate their knowledge of these diseases. A follow them notoriety as a percentage of depression (93% of knowledge), osteoarthritis (91%) and Parkinson (90%).
• When considering only the degree of awareness of neurological diseases, Alzheimer's disease becomes better known (94%), followed by Parkinson (90%) and migraine (87%).
• Although cancer is the most well known disease, by age group highlights that in the groups 35-44 years and 55-64 years of Alzheimer's has greater knowledge, even beyond the cancer and even in this last group Depression of 55-65 to be the best known disease.
Specialist to be used for that type of disease
This section is where you can see one of the most notable changes with respect to the 2005 survey. At that time, only 16% of respondents come from a neurologist to treat diseases such as multiple sclerosis and even surprising answers as to 39% would turn to to deal with this trauma disorder of the nervous system directly and 38% do not know what kind consult. Currently, in the 2008 survey, participants referred to the neurologist have all those diseases of neuronal character. This was followed in the family doctor endorsements.
2008 survey data .-
• Based on all those who have referred to a specialist neurologist who would resort to any of the mentioned types of disease, it is clear that Alzheimer's is where more people would turn from a neurologist (68%), followed by Parkinson ( 58%) and migraine (55%).
• Among the neurological diseases, the MS would be one in which there is less association with the figure of the neurologist, and we find that only 30% would come from a neurologist.
Consideration of the level of severity of neurological disease
In the earlier study, the neurological disease is more serious consideration for respondents was multiple sclerosis, although not known to the specialist who treated with a level of severity of 6.6 on 7 (very severe), almost equal to the severity of the cancer. The new data show that stroke, which is currently the leading cause of death among women, has become the neurological disorder is considered more serious.
2008 survey data .-
• Cancer is a disease considered to be more serious, with an average severity of 6.62 points on a scale from 1 (nothing serious) to 7 (very severe).
• When Cancer is still the level of seriousness with a stroke average of 6.48 and 6.42 of an Alzheimer half seriously.
• Migraines (4.72) and headaches (4.47) are less serious in those types of opinions the interviewees.
• Considering only the nature of neurological diseases, stroke, as discussed above, is considered to be the most serious disease, followed by Alzheimer (6.42 seriousness about 7 points), the MS (6.32) and dementia (6.01 ).
• Although there are no significant differences, it is seen that stroke has a greater impact on severity among women (6.53), those aged 18-24 (6.60), the middle class and low-low (6.60 ) and residents in the South (6.57).
VARIABLES TO HIGHLIGHT
Ratings Neurólogo Vs Other Specialties
• In assessing the specialty of Neurólogo, almost half of those aware of the existence of that particular value as excellent or very good, that percentage rises to 64% if one considers also those that give a good assessment. On a scale of 1-7, the average value is about 5.70 points.
• Only 4% rate the specialty of Neurology as bad or very bad.
• When positioning andalusia Neurólogo compared to others, it would occupy the second position value (average of 5.70 points out of 7) below the trauma (average 5.72) and above other specialists such as the oncologist, ophthalmologist, gynecologist etc..
• Although there are no significant differences, it is women who give an average higher than for men (5.74 to 5.65 for men) and those with 55 and 64 years (5.72).
• In class, out of the middle class and low-low as those that give a higher rating (5.95). They are residents in the Northeast (6.12), South (5.93) and Central (5.80) which have a view of the most valued Neurólogo compared to Northern (4.35).
Expectations and Assessment of Neurologist
• Among the different aspects that are expected to accomplish in the course of visiting the neurologist, include the proper treatment (37% of mentions), followed by the solution to problems (30%) and do everything possible to heal andalusia sick (22%).
• Regarding the priority areas worth a visit to the neurologist, two stand above the rest like the fact that Neurólogo relieve the symptoms of the disease and help prevent disease, both with 27% recall.
Awareness of Neurology
• When asked about the degree of knowledge about the specialty of neurology, 28% of spontaneously mentioned, that percentage rises to 69% when it is suggested that specialty, positioning itself as the first known specialty suggested above other specialties such as rheumatology, gynecology, oncology, etc..
• Considering the total number of mentions (spontaneous + suggested), neurology represents the second most famous specialty of cardiology behind, namely the 82% refers to the specialty of Neurology.
• They come to be aged between 18 and 24 years (87%) and those 35-44 years (87%) which have greater visibility of the specialty of Neurology. Similarly, it is the residents in the East (85%) and South Peninsula (90%) who have greater knowledge.
Source information neurologist and / or neurological diseases
• The principal means by which it is aware of the figure of the neurologist and / or neurological diseases is represented by the family, mentioned in 50% of cases. Followed by information obtained through the doctor (18%) and television, with 15% recall.
• women who are at a significantly higher percentage of men to have consistency across the family (56% vs. 45%). They are people between 25-34 years (57%) and residents of the Northwest (62%) who have also learned through the family.
• The doctor is strongest among young people aged 18-24 (31%) and inhabitants of the North (34%) and television among those 45-54 and 65 and over (19%) and inhabitants of Central and Northeast (19%).
• For that point the doctor as a vehicle of information, names the doctor, followed by the neurologist and specialist in general.
TECHNICAL SURVEY
• Universe: Men and women 18 and older.
• Scope: National level by Nielsen Region (Northwest, Northeast, North, Central, South and East) and habitat size (up to 50,000 inhab. / / 50.001-200.000 / / 200.001-500.000 / / more than 200,000)
• Camp dates: June 2008.
• Sample size: 400n. Interview: Telephonic by CATI system (Computer Assisted Personal Interview
• Sampling: Random stratified multistage Nielsen region, province and size of habitat, by telephone households and individuals by sex and age quotas.
• Responsible Institute: RESEARCH S.A. Member AEDEMO, ESOMAR, The Gallup Organization and received the International Code of Ethics ICC / ESOMAR Marketing and Social Research.
A practical manual of editorial Eduforma MAD offers the keys to living with epilepsy, one of the most common neurological disorders.
The book includes hundreds of questions and answers about a disorder that affects more than 400,000 people in Spain and addresses the issues that patients and families often ask to live with epilepsy
The manual contains specific sections on the impact of the disease in women, children and the elderly, or how to act before an attack
Publishing andaluza reinforces this release with the creation of the web www.mad.es / epilepsy, detailing the work and its author, Anuradha Singh, a specialist at the University of New York
What are the consequences of an epileptic fit? And the risk factors that trigger it? Editorial Eduforma MAD has the answers to these and other issues in his book 100 Questions and answers about epilepsy, a practical manual on one of the most common neurological disorders in the world, only in Spain that affects approximately 400,000 people diagnosed with an incidence of 20,000 new cases annually.
This title Anuradha Singh, a specialist in prestige in the United States collects a hundred questions and answers about the disease, with a strong interest to patients and families affected. The author works in the Global Epilepsy Center, Faculty of Medicine, New York University and is director of the Epilepsy Clinic of the prestigious Bellevue Hospital. The claims that poured into this book answer questions that patients will make in daily practice and helps them to live with this disorder.
The book addresses the disease in three stages, to meet the information needs of each group. Based on each stage of the life cycle of the person diagnosed, the book poses solutions to the childhood to adulthood, with particular attention to the particularities of female-and elderly. Also addresses the various phases of this disorder, ranging from basic studies of diagnosis made by doctors to decide whether or not a patient has epilepsy, to which there are different antiepileptic drugs and their side effects.
Those interested in knowing about this disease will find in this book of the Collection of Health and Family Eduforma Editorial MAD, a real and accessible information on aspects such as symptoms of this disorder, the characteristics of an epileptic fit and first aid if an episode of this type, among other issues of interest to a better understanding of epilepsy.
To reinforce this release, MAD Eduforma Publishing has created a website with details on the contents of the book and its author can be consulted at the address www.mad.es / epilepsy
About MAD Eduforma Editorial
Editorial MAD Eduforma has an experience of over 26 years in publishing books with a practical orientation. Gradually has enriched its extensive catalog to create different collections such as the Health and Family, which owns the book 100 Questions and answers about epilepsy, including titles like 100 questions and answers about asthma in children or 100 questions and answers about psoriasis.
The manual contains specific sections on the impact of the disease in women, children and the elderly, or how to act before an attack
Publishing andaluza reinforces this release with the creation of the web www.mad.es / epilepsy, detailing the work and its author, Anuradha Singh, a specialist at the University of New York
What are the consequences of an epileptic fit? And the risk factors that trigger it? Editorial Eduforma MAD has the answers to these and other issues in his book 100 Questions and answers about epilepsy, a practical manual on one of the most common neurological disorders in the world, only in Spain that affects approximately 400,000 people diagnosed with an incidence of 20,000 new cases annually.
This title Anuradha Singh, a specialist in prestige in the United States collects a hundred questions and answers about the disease, with a strong interest to patients and families affected. The author works in the Global Epilepsy Center, Faculty of Medicine, New York University and is director of the Epilepsy Clinic of the prestigious Bellevue Hospital. The claims that poured into this book answer questions that patients will make in daily practice and helps them to live with this disorder.
The book addresses the disease in three stages, to meet the information needs of each group. Based on each stage of the life cycle of the person diagnosed, the book poses solutions to the childhood to adulthood, with particular attention to the particularities of female-and elderly. Also addresses the various phases of this disorder, ranging from basic studies of diagnosis made by doctors to decide whether or not a patient has epilepsy, to which there are different antiepileptic drugs and their side effects.
Those interested in knowing about this disease will find in this book of the Collection of Health and Family Eduforma Editorial MAD, a real and accessible information on aspects such as symptoms of this disorder, the characteristics of an epileptic fit and first aid if an episode of this type, among other issues of interest to a better understanding of epilepsy.
To reinforce this release, MAD Eduforma Publishing has created a website with details on the contents of the book and its author can be consulted at the address www.mad.es / epilepsy
About MAD Eduforma Editorial
Editorial MAD Eduforma has an experience of over 26 years in publishing books with a practical orientation. Gradually has enriched its extensive catalog to create different collections such as the Health and Family, which owns the book 100 Questions and answers about epilepsy, including titles like 100 questions and answers about asthma in children or 100 questions and answers about psoriasis.
The fixed-dose combination of an inhibitor with amlodipine SRA offers patients better cardiovascular protection than the combination with a diuretic.
Accomplish is the first study that compares results of fixed-dose combinations of an inhibitor of the renin angiotensin system (RAS) to reduce the episodes cardiovasculares1
The combination of a RAS inhibitor with amlodipine reduced by 20% the risk of cardiovascular events in high risk patients, compared with the combination of an inhibitor of the RAS with diurético1
The results accomplished, published in New England Journal of Medicine, show that with fixed-dose combinations, approximately twice of patients achieved the target blood pressure than with previous monotherapy or politerapias1
Patients treated with each of the fixed-dose combinations achieved a mean systolic blood pressure of 130 mmHg1
Accomplish the final results of the first study comparing fixed-dose combinations of antihypertensive drugs in reducing cardiovascular events (CV) have shown that an inhibitor of the renin-angiotensin system (RAS), benazepril combined with amlodipine reduced BESILATE BESYLATE of 20 % CV events such as myocardial infarction and stroke in hypertensive patients at high risk, compared with a combination of RAS inhibitor with hydrochlorothiazide (HCT) 1
The results of accomplish (Avoiding Cardiovascular Events through Combination Therapy in Patients Living With systolic Hypertension; Avoiding cardiovascular events with combination therapy in patients with systolic hypertension), published today in The New England Journal of Medicine, show that some patients were able to double the target blood pressure with a fixed-dose combination compared with their previous antihypertensive treatment, irrespective of whether they were alone or politerapia.1
At the start of the study, only 37% of patients met the target of systolic pressure <140 mmHg.1 After switching to a fixed-dose combination, 72% (combination with HCT) and 75% (combination with amlodipine) of patients achieved the target blood pressure at the end of the trial, with a mean value of systolic pressure of 130 mmHg.1
It is the first study results in a large scale and achieves a value of pressure sistólica.1 systolic blood pressure is a measure of the maximum force exerted against the heart beats when the glasses. This result is very significant because the systolic pressure increases with age and is an important indicator of the risk that a person present episodes CV.2 Indeed, hypertension (HTA) is one of the most important risk factors, but treatable of CV disease (the leading cause of death worldwide) 3
Experience says Barrios, a cardiologist at the Hospital Ramón y Cajal de Madrid, accomplish results open interesting new perspectives on the utility of using fixed combinations in the initial treatment of hypertension in high risk patients, unlike the monotherapy, which is what usually does. "
The cardiologist noted that Barrios Experience the study reached an excellent level in controlling the numbers of blood pressure in more than 72% of patients at high risk. "
Examples of inhibitors of the SRA are receptor antagonists of angiotensin (ARA-II, such as valsartan (Diovan ®) and inhibitors of angiotensin converting enzyme (ACE inhibitors such as benazepril). It has been observed that through inhibition of RAS with a single O-II or an ACE inhibitor reduces episodes CV.4-7 However, more than half of hypertensive patients may need polytherapy to achieve the goals of pressure arterial.8
Patients may have greater compliance, if they take their medication in a single tablet that when there are two different tablets, 9 but so far there had been no test results that support the early use of fixed-dose combinations in the course treatment. On accomplished, half the patients achieved their goal of taking blood pressure medication in a single tablet, ie without any treatment adicional.10 addition, approximately 70% of patients taking the combination at the end of estudio.1
The two fixed-dose combinations were well tolerated. The incidence of adverse events that led to the withdrawal of the study was low, approximately 15% of both groups and only 0.5% (combination with HCT) and 0.4% (combination with amlodipine) experienced adverse events such as hypotension grave.1
"For patients with hypertension who need simple and effective therapeutic strategies to help reduce the risk of CV events, the results indicate that accomplish a fixed-dose combination of an RAS inhibitor and amlodipine is an effective option, well tolerated and convenient, "said Dr. Ameet Nathwani, director of international franchise development and Cardiovascular Metabolism Novartis Pharma AG.
Novartis' confidence in the strategy of fixed-dose combination is reflected in the success of two of its antihypertensive: Exforge ®, the first fixed combination of valsartan and amlodipine and Co-Diovan ® (Diovan plus hydrochlorothiazide). Both Exforge ® as Co-Diovan ® has been recently approved in USA for first-line use in patients likely to require polytherapy to achieve their goal blood pressure. Exforge ® is a new combination therapy (valsartan and amlodipine), which gives patients the opportunity to better control your blood pressure and allows for greater tolerability and adherence to treatment. In Spain, Exforge ® is indicated in patients whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy, while Co-Diovan ® is indicated in patients whose blood pressure is not adequately controlled with valsartan monotherapy.
Novartis is dedicated to improving the lives of hundreds of millions of people with CV and metabolic diseases through medicines and effective programs, and its continued commitment to research. As a global leader in CV and metabolic health for nearly 50 years, Novartis provides innovative therapies and support programs to treat hypertension and diabetes, two major public health problems.
The product portfolio Novartis is focused on drugs for cardiovascular disease, specifically for the treatment of hypertension and diabetes: Exforge ®, and Co-Diovan ® and Diovan ® Rasilez ® (aliskiren) the first and only direct inhibitor renin and authorized a new DPP-4 inhibitor Galvus ® (vildagliptin, which is also available as a fixed dose combination with metformin, Eucreas ®).
About accomplish
Accomplish is a test based on events, multicenter, multinational, randomized, double blind, which has involved more than 11,000 patients from 550 centers around the U.S. and Scandinavian countries. The evaluation criteria included composite of myocardial infarction, stroke, hospitalizations for unstable angina pectoris and CV death in hypertensive patients at high risk. This is the first test results in a CV hypertensive population, in which all patients were randomized to receive a fixed-dose combination therapy at the beginning of the test rather than a therapeutic staggered pattern. Patients received a fixed dose combination of an RAS inhibitor (benazepril) with BESILATE BESYLATE of amlodipine or same RAS inhibitor with HCT. In the first 2 months of the study, increased doses of drugs for study: the inhibitor of the renin-angiotensin system was increased gradually to 40 mg and subsequently in patients who did not achieve the target blood pressure was increased gradually HCT 25 mg and amlodipine 10 mg.
Bibliography
1 Jamerson K et al. Or Amlodipine Benazepril plus hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med 2008, 359:2417-28.
2 Williams B et al. Systolic pressure is all that matters. Lancet 2008, 371:2219-21.
3 World Health Organization. Cardiovascular Disease Factsheet. Accessed:
http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
4 Yusuf S et al. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in
high risk patients. N Engl J Med 2000, 342:145-53.
5 Fox KM et al. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable
coronary artery disease, randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA
study). Lancet 2003; 362:782-8.
6 Cohn J et al. A randomized trial of the angiotensin-receptor-blocker valsartan in chronic heart failure. N
Engl J Med 2001, 345:1667-75.
7 Pfeffer MA et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left
ventricular dysfunction, or both. N Engl J Med 2003; 349 (20) :1893-906.
8 Dahlöf B et al. Prevention of cardiovascular events with an Antihypertensive regimen of adding Amlodipine
Perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized
controlled trial. Lancet 2005, 366:895-906
9 Arshad S et al. Comparison of effectiveness and safety of fixed-dose combinations of Antihypertensive
agents with the free-drug combination of its components when given separately in hypertensive patients: a
meta-analysis of 32 134 patients. J Human Hypertens 2008, 22: S1-S12. Abstract # 5.3.
10 Jamerson KA. Accomplish Late Breaking Presentation at ACC, March 31, 2008.
The combination of a RAS inhibitor with amlodipine reduced by 20% the risk of cardiovascular events in high risk patients, compared with the combination of an inhibitor of the RAS with diurético1
The results accomplished, published in New England Journal of Medicine, show that with fixed-dose combinations, approximately twice of patients achieved the target blood pressure than with previous monotherapy or politerapias1
Patients treated with each of the fixed-dose combinations achieved a mean systolic blood pressure of 130 mmHg1
Accomplish the final results of the first study comparing fixed-dose combinations of antihypertensive drugs in reducing cardiovascular events (CV) have shown that an inhibitor of the renin-angiotensin system (RAS), benazepril combined with amlodipine reduced BESILATE BESYLATE of 20 % CV events such as myocardial infarction and stroke in hypertensive patients at high risk, compared with a combination of RAS inhibitor with hydrochlorothiazide (HCT) 1
The results of accomplish (Avoiding Cardiovascular Events through Combination Therapy in Patients Living With systolic Hypertension; Avoiding cardiovascular events with combination therapy in patients with systolic hypertension), published today in The New England Journal of Medicine, show that some patients were able to double the target blood pressure with a fixed-dose combination compared with their previous antihypertensive treatment, irrespective of whether they were alone or politerapia.1
At the start of the study, only 37% of patients met the target of systolic pressure <140 mmHg.1 After switching to a fixed-dose combination, 72% (combination with HCT) and 75% (combination with amlodipine) of patients achieved the target blood pressure at the end of the trial, with a mean value of systolic pressure of 130 mmHg.1
It is the first study results in a large scale and achieves a value of pressure sistólica.1 systolic blood pressure is a measure of the maximum force exerted against the heart beats when the glasses. This result is very significant because the systolic pressure increases with age and is an important indicator of the risk that a person present episodes CV.2 Indeed, hypertension (HTA) is one of the most important risk factors, but treatable of CV disease (the leading cause of death worldwide) 3
Experience says Barrios, a cardiologist at the Hospital Ramón y Cajal de Madrid, accomplish results open interesting new perspectives on the utility of using fixed combinations in the initial treatment of hypertension in high risk patients, unlike the monotherapy, which is what usually does. "
The cardiologist noted that Barrios Experience the study reached an excellent level in controlling the numbers of blood pressure in more than 72% of patients at high risk. "
Examples of inhibitors of the SRA are receptor antagonists of angiotensin (ARA-II, such as valsartan (Diovan ®) and inhibitors of angiotensin converting enzyme (ACE inhibitors such as benazepril). It has been observed that through inhibition of RAS with a single O-II or an ACE inhibitor reduces episodes CV.4-7 However, more than half of hypertensive patients may need polytherapy to achieve the goals of pressure arterial.8
Patients may have greater compliance, if they take their medication in a single tablet that when there are two different tablets, 9 but so far there had been no test results that support the early use of fixed-dose combinations in the course treatment. On accomplished, half the patients achieved their goal of taking blood pressure medication in a single tablet, ie without any treatment adicional.10 addition, approximately 70% of patients taking the combination at the end of estudio.1
The two fixed-dose combinations were well tolerated. The incidence of adverse events that led to the withdrawal of the study was low, approximately 15% of both groups and only 0.5% (combination with HCT) and 0.4% (combination with amlodipine) experienced adverse events such as hypotension grave.1
"For patients with hypertension who need simple and effective therapeutic strategies to help reduce the risk of CV events, the results indicate that accomplish a fixed-dose combination of an RAS inhibitor and amlodipine is an effective option, well tolerated and convenient, "said Dr. Ameet Nathwani, director of international franchise development and Cardiovascular Metabolism Novartis Pharma AG.
Novartis' confidence in the strategy of fixed-dose combination is reflected in the success of two of its antihypertensive: Exforge ®, the first fixed combination of valsartan and amlodipine and Co-Diovan ® (Diovan plus hydrochlorothiazide). Both Exforge ® as Co-Diovan ® has been recently approved in USA for first-line use in patients likely to require polytherapy to achieve their goal blood pressure. Exforge ® is a new combination therapy (valsartan and amlodipine), which gives patients the opportunity to better control your blood pressure and allows for greater tolerability and adherence to treatment. In Spain, Exforge ® is indicated in patients whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy, while Co-Diovan ® is indicated in patients whose blood pressure is not adequately controlled with valsartan monotherapy.
Novartis is dedicated to improving the lives of hundreds of millions of people with CV and metabolic diseases through medicines and effective programs, and its continued commitment to research. As a global leader in CV and metabolic health for nearly 50 years, Novartis provides innovative therapies and support programs to treat hypertension and diabetes, two major public health problems.
The product portfolio Novartis is focused on drugs for cardiovascular disease, specifically for the treatment of hypertension and diabetes: Exforge ®, and Co-Diovan ® and Diovan ® Rasilez ® (aliskiren) the first and only direct inhibitor renin and authorized a new DPP-4 inhibitor Galvus ® (vildagliptin, which is also available as a fixed dose combination with metformin, Eucreas ®).
About accomplish
Accomplish is a test based on events, multicenter, multinational, randomized, double blind, which has involved more than 11,000 patients from 550 centers around the U.S. and Scandinavian countries. The evaluation criteria included composite of myocardial infarction, stroke, hospitalizations for unstable angina pectoris and CV death in hypertensive patients at high risk. This is the first test results in a CV hypertensive population, in which all patients were randomized to receive a fixed-dose combination therapy at the beginning of the test rather than a therapeutic staggered pattern. Patients received a fixed dose combination of an RAS inhibitor (benazepril) with BESILATE BESYLATE of amlodipine or same RAS inhibitor with HCT. In the first 2 months of the study, increased doses of drugs for study: the inhibitor of the renin-angiotensin system was increased gradually to 40 mg and subsequently in patients who did not achieve the target blood pressure was increased gradually HCT 25 mg and amlodipine 10 mg.
Bibliography
1 Jamerson K et al. Or Amlodipine Benazepril plus hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med 2008, 359:2417-28.
2 Williams B et al. Systolic pressure is all that matters. Lancet 2008, 371:2219-21.
3 World Health Organization. Cardiovascular Disease Factsheet. Accessed:
http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
4 Yusuf S et al. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in
high risk patients. N Engl J Med 2000, 342:145-53.
5 Fox KM et al. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable
coronary artery disease, randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA
study). Lancet 2003; 362:782-8.
6 Cohn J et al. A randomized trial of the angiotensin-receptor-blocker valsartan in chronic heart failure. N
Engl J Med 2001, 345:1667-75.
7 Pfeffer MA et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left
ventricular dysfunction, or both. N Engl J Med 2003; 349 (20) :1893-906.
8 Dahlöf B et al. Prevention of cardiovascular events with an Antihypertensive regimen of adding Amlodipine
Perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized
controlled trial. Lancet 2005, 366:895-906
9 Arshad S et al. Comparison of effectiveness and safety of fixed-dose combinations of Antihypertensive
agents with the free-drug combination of its components when given separately in hypertensive patients: a
meta-analysis of 32 134 patients. J Human Hypertens 2008, 22: S1-S12. Abstract # 5.3.
10 Jamerson KA. Accomplish Late Breaking Presentation at ACC, March 31, 2008.
A new model for streamlining and improving the quality of death certificates.
• There will be only to fill a single form for the certification of death for registration for statistical purposes. Enter into force next January 1 and will be distributed, as now, through the Colleges of Physicians
The National Statistics Institute (INE) and the General Council of Colleges of Physicians (CGCOM) have reached an agreement to launch a new set of "Medical Certificate of Death / Death Statistics Bulletin," so as to delete the current task being undertaken by doctors in this area and have a unique tool used to register both functions. This implies not only a breakthrough in the simplification of tasks but also in improving quality.
Currently, the law distinguishes between the death registration and certification thereof. In this way, the task of certifying doctors was doubled because of a party must certify the death in the corresponding medical certificate of death and otherwise, have to fill in the section on causes of death in the Statistical Bulletin of Deaths .
There are two official statistics on deaths, compiled by the INE: Natural Movement of Population (births, deaths, marriages) and Deaths by cause of death. For both statistics using the Statistical Bulletin of Deaths, part of which-in particular on the causes of death-to be completed by the medical certifier. For his part, CGCOM as Public Law Corporation, is the only body authorized to edit and distribute the forms of medical officers, including the medical certificate of death "will be used to prove that, with the requirements and impacts identified in existing laws and regulations. "
Therefore, given the need to eliminate this task and establish a new form of more rapid and effective action, within the competences of each part, and NSIs CGCOM have agreed to produce and edit a new set of Certified Doctor Death and Statistical Bulletin in order to provide a single document for both the registration of death in the Civil Registry to compile statistics of the Natural Movement of Population.
The new series will run for instructions for death to occur in the civil registers from January 1 2009 and will CGCOM distribution through the Colleges of Physicians in the same way as is being done in currently with the medical certificate of death.
The signing of the agreement and presentation has been delivered by the Chairman of the National Institute of Statistics, Jaume García Villar and Vice President of the General Council of Medical Colleges, Ricard Gutierrez in a ceremony held at the headquarters of the Medical School.
Quality and certification
Certification is a medical act, subject to the requirements contained in the statutory and ethical standards of the Medical College Organization (WTO), and in particular to the provisions of Title VI of the General Statutes (art.58-61) and in the current Code of Ethics and Medical Ethics of the Medical College Organization (Article 11). The medical certificate of death is a document subject to the rules of professional responsibility. CERTIFY clause in the medical report gives you the value of a legally-certified and as such, public document and provides a supplement to its content testimonial guarantee and commitment.
Considering the importance of death certificates to understand the causes of death and its determinants, the WTO will initiate an immediate update of a training strategy to improve the quality and content of certificates.
The National Statistics Institute (INE) and the General Council of Colleges of Physicians (CGCOM) have reached an agreement to launch a new set of "Medical Certificate of Death / Death Statistics Bulletin," so as to delete the current task being undertaken by doctors in this area and have a unique tool used to register both functions. This implies not only a breakthrough in the simplification of tasks but also in improving quality.
Currently, the law distinguishes between the death registration and certification thereof. In this way, the task of certifying doctors was doubled because of a party must certify the death in the corresponding medical certificate of death and otherwise, have to fill in the section on causes of death in the Statistical Bulletin of Deaths .
There are two official statistics on deaths, compiled by the INE: Natural Movement of Population (births, deaths, marriages) and Deaths by cause of death. For both statistics using the Statistical Bulletin of Deaths, part of which-in particular on the causes of death-to be completed by the medical certifier. For his part, CGCOM as Public Law Corporation, is the only body authorized to edit and distribute the forms of medical officers, including the medical certificate of death "will be used to prove that, with the requirements and impacts identified in existing laws and regulations. "
Therefore, given the need to eliminate this task and establish a new form of more rapid and effective action, within the competences of each part, and NSIs CGCOM have agreed to produce and edit a new set of Certified Doctor Death and Statistical Bulletin in order to provide a single document for both the registration of death in the Civil Registry to compile statistics of the Natural Movement of Population.
The new series will run for instructions for death to occur in the civil registers from January 1 2009 and will CGCOM distribution through the Colleges of Physicians in the same way as is being done in currently with the medical certificate of death.
The signing of the agreement and presentation has been delivered by the Chairman of the National Institute of Statistics, Jaume García Villar and Vice President of the General Council of Medical Colleges, Ricard Gutierrez in a ceremony held at the headquarters of the Medical School.
Quality and certification
Certification is a medical act, subject to the requirements contained in the statutory and ethical standards of the Medical College Organization (WTO), and in particular to the provisions of Title VI of the General Statutes (art.58-61) and in the current Code of Ethics and Medical Ethics of the Medical College Organization (Article 11). The medical certificate of death is a document subject to the rules of professional responsibility. CERTIFY clause in the medical report gives you the value of a legally-certified and as such, public document and provides a supplement to its content testimonial guarantee and commitment.
Considering the importance of death certificates to understand the causes of death and its determinants, the WTO will initiate an immediate update of a training strategy to improve the quality and content of certificates.
Tuesday, February 10, 2009
Pharmaceutical sector in Turkey
ARAŞTIRMACILAR Pharmaceutical Companies Association (AİFD) Chairman Dr Pharmacists. According to the information Demirdere'nin altan:
Approximately U.S. $ 5.5 billion in consumer prices in Turkey are consumed drugs. On the other hand, annual cigarette consumption in Turkey U.S. $ 8 billion, annual alcohol consumption is 10 billion U.S. $.
This money is spent on medication, both in total and per capita, less than 4 times compared to other countries. Also, compared to other countries, in Turkey there is less drug types. However, total health expenditures in Turkey in the share of drug compared to 2 times more than other countries.
The main reason, drugs are expensive, or not much expenses, total health spending is insufficient. Total health expenditure 8.5% of GDP in other countries' u is lower than in Turkey, although other countries, around 4% of GNP.
Rate in Turkey to meet the pharmaceutical exports and imports is very low and around 10%.
Indian generic drugs produced in the original and almost all of the active substances are being imported from abroad.
17% of the world such as the pharmaceutical sector, the vast majority of turnover research and development expenditures is the only industry. This rate of 10.5% even in computer software, electric-electronic industry 8.4%!
Share in the value of drugs imported from Turkey, some 38%, 12% of box basis. The figures below normal limits in the world. Extremely important as an original and generic pharmaceutical industry in Germany has to pay for imported drugs as 45th%
However, the share of generics in Turkey is around 45% by value, while the European average, and the United States this figure is 30% in value (Germany and the UK is around 20s%).
Clinical Research 40 billion in total spending is $. Our country only 1% of total clinical research in the country in case we can bring $ 400 million be transferred would be possible.
* * *
9th of 19 January 2005 Licensing Regulations According to Article generic drug manufacturers have resisted for years, but the defense insists that the EU 'medicine of data protection' to be applied from this date, our country has been adopted. However, someone from the Ministry of Health and wiliness etmiş According to the figures does not reveal, to some 300 by 1200 according to some generic application is still compressed to.
The EU claims they can not be absolutely license!
Ministry of Health is not yet clear what will!
Secretary-General says Engin Guner AİFD:
'Fictitious claims should not be considered absolutely. Only with all the necessary reports and documents biyoeşdeğerlik report has been submitted to serious consideration of the application-application in 1000, but in short, maybe 20-30 a solution can be found is a serious guarantee application-I am thinking. This is my my opinion.
Thus, the European Court of Justice on the EU's drive to the left in a difficult situation, such as Turkey, I think growth can be prevented. "
* * *
Obviously, Turkey can not escape in a game but still had contact with Ali Cengiz oyunu hand man does not eat!
Approximately U.S. $ 5.5 billion in consumer prices in Turkey are consumed drugs. On the other hand, annual cigarette consumption in Turkey U.S. $ 8 billion, annual alcohol consumption is 10 billion U.S. $.
This money is spent on medication, both in total and per capita, less than 4 times compared to other countries. Also, compared to other countries, in Turkey there is less drug types. However, total health expenditures in Turkey in the share of drug compared to 2 times more than other countries.
The main reason, drugs are expensive, or not much expenses, total health spending is insufficient. Total health expenditure 8.5% of GDP in other countries' u is lower than in Turkey, although other countries, around 4% of GNP.
Rate in Turkey to meet the pharmaceutical exports and imports is very low and around 10%.
Indian generic drugs produced in the original and almost all of the active substances are being imported from abroad.
17% of the world such as the pharmaceutical sector, the vast majority of turnover research and development expenditures is the only industry. This rate of 10.5% even in computer software, electric-electronic industry 8.4%!
Share in the value of drugs imported from Turkey, some 38%, 12% of box basis. The figures below normal limits in the world. Extremely important as an original and generic pharmaceutical industry in Germany has to pay for imported drugs as 45th%
However, the share of generics in Turkey is around 45% by value, while the European average, and the United States this figure is 30% in value (Germany and the UK is around 20s%).
Clinical Research 40 billion in total spending is $. Our country only 1% of total clinical research in the country in case we can bring $ 400 million be transferred would be possible.
* * *
9th of 19 January 2005 Licensing Regulations According to Article generic drug manufacturers have resisted for years, but the defense insists that the EU 'medicine of data protection' to be applied from this date, our country has been adopted. However, someone from the Ministry of Health and wiliness etmiş According to the figures does not reveal, to some 300 by 1200 according to some generic application is still compressed to.
The EU claims they can not be absolutely license!
Ministry of Health is not yet clear what will!
Secretary-General says Engin Guner AİFD:
'Fictitious claims should not be considered absolutely. Only with all the necessary reports and documents biyoeşdeğerlik report has been submitted to serious consideration of the application-application in 1000, but in short, maybe 20-30 a solution can be found is a serious guarantee application-I am thinking. This is my my opinion.
Thus, the European Court of Justice on the EU's drive to the left in a difficult situation, such as Turkey, I think growth can be prevented. "
* * *
Obviously, Turkey can not escape in a game but still had contact with Ali Cengiz oyunu hand man does not eat!
Pharmaceutical sector was met with double-barcode
Automatic identification and data collection industry's leading companies in the world, Turkey distributor Boer Electronics, held on 13-16 November 9th Turkey participated in the Congress of Pharmacy, the couple will enter the year 2009 since the implementation of solutions related to barcode system was introduced.
Be the largest in Turkey with the participation of Congress and 13 - 16 November WOW Hotels & Convention Center on the 9th place in Yesilkoy Turkey Pharmaceuticals meet Congress the Boer Electronics pharmacists, pharmacy stores and pharmacies to be read by barcode Karekod offer the opportunity to promote the different solutions found.
At the beginning of 2009 to be implemented according to the prescribed system, no medicine "secondary identification" (bar code) will not be printed without. Current barcode system, only its own stocks of companies, products, and sales are tracked, 'Dual barcode' system of drug selling, store, export or import of any of pharmacy with all the movement to a centralized system (Drug Tracking System) will be notified.
Be the largest in Turkey with the participation of Congress and 13 - 16 November WOW Hotels & Convention Center on the 9th place in Yesilkoy Turkey Pharmaceuticals meet Congress the Boer Electronics pharmacists, pharmacy stores and pharmacies to be read by barcode Karekod offer the opportunity to promote the different solutions found.
At the beginning of 2009 to be implemented according to the prescribed system, no medicine "secondary identification" (bar code) will not be printed without. Current barcode system, only its own stocks of companies, products, and sales are tracked, 'Dual barcode' system of drug selling, store, export or import of any of pharmacy with all the movement to a centralized system (Drug Tracking System) will be notified.
AİFD: 2008 for the pharmaceutical sector
ISTANBUL (UAV) - Researchers Pharmaceutical Companies Association (AİFD), 2008 an important year for Turkey in the pharmaceutical sector will be made.
AİFD'den made in 2008 on health reform, improve the investment environment and the sector on measures to improve the global competitiveness should be pointed out that serious progress has been.
In 2008 the pharmaceutical sector in Turkey will be an important recording AİFD, Turkey's innovative drug research, development and production as a global power, in other countries of the developed technology and products among the audience of a way to stay in the said separation.
AİFD in 2008 to discover new drugs and to investigate global-scale investment of nearly 70 billion dollars to do that and call for the trial stage of cancer in more than 600 new medicines to the island, more than 6 thousand of new drug candidates under development said.
New production centers, equipment and renovation will be done this year for the investment of billions of dollars is added in 2008 in the innovative pharmaceutical industry about $ 100 billion at the global level, in the amount of investment is expected to be made.
Issues related to evaluating the Secretary-General AİFD Engin Güner, "Turkey in 2008 in the innovative pharmaceutical sector to competition and health sciences in the global investment rather than a greater share of opportunities to catch. However, this decision of a global race and that Turkey's successful compete for the right vision, strategy and policies should be implemented must be able to see a clear way, "he said.
"Turkey for new drugs in 2007 for 1 percent of global investments attract a lower rate than the very advanced stages of clinical research in the direction of funds to the approximately 27 million dollars, only able to receive" says Engin Guner, "from Turkey in total exports of generic and innovative pharmaceutical 350 million the dollar was lower. Turkey's much smaller than Ireland and that of countries like Singapore drug exports billions of dollars to overcome. Ireland's pharmaceutical export chemicals with 50 billion dollars to overcome. This country's domestic drug consumption financing exports rapidly growing support from drug production tax from the to provide, "he spoke.
"2008, a critical year of decision"
Guner, "AİFD, Turkey, Health Sciences is a competitor in the global position as the past 2 years many proposals were submitted. The future to keep things light with innovative medicines and health sciences industry to develop the potential for many constructive activities, and have offered suggestions. Ülkemizin truly first-class quality to have in an innovative pharmaceutical industry is our most important priorities at this stage "as it had not.
Secretary General Engin Güner AİFD sector can reach a more advanced point in the following order of priority objectives are:
"New drugs are licensed from 2-3 years and be paid back in 6-9 months to licensing reform,
Accelerate the process of harmonization with EU standards, waiting a long time, clinical research for the realization of legal arrangements to raise standards, tax incentives,
To attract international investment in Turkey, to investigate innovative drugs, the leading country in production and exports among other measures to ensure access. "
"In Singapore, if a new drug known worldwide, such as FDA and EMEA approval of the organization has received as little as 2 months at a time to be produced and marketed for licenses in Turkey, this time in 2 years can take up to" said the new production Güner evaluate decisions in terms of the company, 2 months and 2 years was the difference between the points to the importance of.
Turkey yaşadığı's brain drain problem attracts the attention Güner, "Our country medicine and science in the field of rich human resources has. But support policies because of the lack of these people, research and development efforts in large part to do abroad. Turkey in more R & D investments to encourage there is a need for new policies, "he said.
In Turkey, the innovative pharmaceutical industry and life sciences in terms of the assessment in 2007 that Güner, "the good way of work in 2007 of the proposed decision to listen more carefully to be started, and Turkey, a world class competitors are seeing could be. However, the investment environment to improve a little more concrete step did not. Yet the world pharmaceutical industry experienced a serious competition does. innovative pharmaceutical industry, Ireland, Singapore, China or India in the ongoing new investments are made. We in our country for the pharmaceutical sector road map for establishing as always, will contribute. our government to us, a critical decision The correct year 2008 and long-term policies to put into practice hope. Ireland or Singapore as models of innovative medicines covered by evaluating and implementing the right policies, Turkey innovative drugs in the new investments may be about 1 billion dollars, "he spoke.
AİFD'den made in 2008 on health reform, improve the investment environment and the sector on measures to improve the global competitiveness should be pointed out that serious progress has been.
In 2008 the pharmaceutical sector in Turkey will be an important recording AİFD, Turkey's innovative drug research, development and production as a global power, in other countries of the developed technology and products among the audience of a way to stay in the said separation.
AİFD in 2008 to discover new drugs and to investigate global-scale investment of nearly 70 billion dollars to do that and call for the trial stage of cancer in more than 600 new medicines to the island, more than 6 thousand of new drug candidates under development said.
New production centers, equipment and renovation will be done this year for the investment of billions of dollars is added in 2008 in the innovative pharmaceutical industry about $ 100 billion at the global level, in the amount of investment is expected to be made.
Issues related to evaluating the Secretary-General AİFD Engin Güner, "Turkey in 2008 in the innovative pharmaceutical sector to competition and health sciences in the global investment rather than a greater share of opportunities to catch. However, this decision of a global race and that Turkey's successful compete for the right vision, strategy and policies should be implemented must be able to see a clear way, "he said.
"Turkey for new drugs in 2007 for 1 percent of global investments attract a lower rate than the very advanced stages of clinical research in the direction of funds to the approximately 27 million dollars, only able to receive" says Engin Guner, "from Turkey in total exports of generic and innovative pharmaceutical 350 million the dollar was lower. Turkey's much smaller than Ireland and that of countries like Singapore drug exports billions of dollars to overcome. Ireland's pharmaceutical export chemicals with 50 billion dollars to overcome. This country's domestic drug consumption financing exports rapidly growing support from drug production tax from the to provide, "he spoke.
"2008, a critical year of decision"
Guner, "AİFD, Turkey, Health Sciences is a competitor in the global position as the past 2 years many proposals were submitted. The future to keep things light with innovative medicines and health sciences industry to develop the potential for many constructive activities, and have offered suggestions. Ülkemizin truly first-class quality to have in an innovative pharmaceutical industry is our most important priorities at this stage "as it had not.
Secretary General Engin Güner AİFD sector can reach a more advanced point in the following order of priority objectives are:
"New drugs are licensed from 2-3 years and be paid back in 6-9 months to licensing reform,
Accelerate the process of harmonization with EU standards, waiting a long time, clinical research for the realization of legal arrangements to raise standards, tax incentives,
To attract international investment in Turkey, to investigate innovative drugs, the leading country in production and exports among other measures to ensure access. "
"In Singapore, if a new drug known worldwide, such as FDA and EMEA approval of the organization has received as little as 2 months at a time to be produced and marketed for licenses in Turkey, this time in 2 years can take up to" said the new production Güner evaluate decisions in terms of the company, 2 months and 2 years was the difference between the points to the importance of.
Turkey yaşadığı's brain drain problem attracts the attention Güner, "Our country medicine and science in the field of rich human resources has. But support policies because of the lack of these people, research and development efforts in large part to do abroad. Turkey in more R & D investments to encourage there is a need for new policies, "he said.
In Turkey, the innovative pharmaceutical industry and life sciences in terms of the assessment in 2007 that Güner, "the good way of work in 2007 of the proposed decision to listen more carefully to be started, and Turkey, a world class competitors are seeing could be. However, the investment environment to improve a little more concrete step did not. Yet the world pharmaceutical industry experienced a serious competition does. innovative pharmaceutical industry, Ireland, Singapore, China or India in the ongoing new investments are made. We in our country for the pharmaceutical sector road map for establishing as always, will contribute. our government to us, a critical decision The correct year 2008 and long-term policies to put into practice hope. Ireland or Singapore as models of innovative medicines covered by evaluating and implementing the right policies, Turkey innovative drugs in the new investments may be about 1 billion dollars, "he spoke.
Pharmaceutical sector
* Pharmaceutical sector size of 10.9 billion USD in 2007.
* Turkey's in 2010 is expected to rise to 10, the first world drug consumption.
* 2006, 1.2 billion boxes are selling drugs, in 2007 this figure was 1.3 billion dollars.
* Sector 8 percent in 2007 box basis, the amount, basis, grew at a rate of 14.5 percent.
Annual per capita drug consumption in Europe is * 500, U.S. 900, and 100 dollars in Turkey.
* 20 largest pharmaceutical companies in Turkey belong to the 15 foreigners.
* In Turkey, public health expenditure in total drug spending in the known rate of around 25 per cent.
700 million U.S. $ at medicine in the trash are
Vice President of TEB Şevket Kaya, Turkey 700 million dollars in drugs each year is a waste, even opened the package of drugs to 15%, he said.
Turkish Pharmacists Association (TEB) The second President Şevket Kaya, Turkey's pharmaceutical market is around 10 billion dollars announced. "In our country, pharmaceutical waste 500 to 700 million dollars between. This is around 10 billion dollars in the market for a very high figure" said the rock, although provision system comes into play after this, such as reduced waste, but also in comparison to EU countries, more drugs in the trash Go said.
Unconscious is consumed
In Turkey a waste of the unconscious drug consumption caused by the stresses that the rock, said: "House of drugs in 15 percent never open the package without the 25 per cent, leaving the half is a waste. Waste of drugs during the first drugs in the stomach, the second in painkillers Coming in third and antibiotics. " A problem specific to the pharmaceutical waste is not only Turkey indicating rocks, especially in Asian countries has made the world is experiencing this hardship. Kaya, see injustice in the world of medicine is available, the least developed countries is experiencing difficulty in reaching the drugs in question added.
* Turkey's in 2010 is expected to rise to 10, the first world drug consumption.
* 2006, 1.2 billion boxes are selling drugs, in 2007 this figure was 1.3 billion dollars.
* Sector 8 percent in 2007 box basis, the amount, basis, grew at a rate of 14.5 percent.
Annual per capita drug consumption in Europe is * 500, U.S. 900, and 100 dollars in Turkey.
* 20 largest pharmaceutical companies in Turkey belong to the 15 foreigners.
* In Turkey, public health expenditure in total drug spending in the known rate of around 25 per cent.
700 million U.S. $ at medicine in the trash are
Vice President of TEB Şevket Kaya, Turkey 700 million dollars in drugs each year is a waste, even opened the package of drugs to 15%, he said.
Turkish Pharmacists Association (TEB) The second President Şevket Kaya, Turkey's pharmaceutical market is around 10 billion dollars announced. "In our country, pharmaceutical waste 500 to 700 million dollars between. This is around 10 billion dollars in the market for a very high figure" said the rock, although provision system comes into play after this, such as reduced waste, but also in comparison to EU countries, more drugs in the trash Go said.
Unconscious is consumed
In Turkey a waste of the unconscious drug consumption caused by the stresses that the rock, said: "House of drugs in 15 percent never open the package without the 25 per cent, leaving the half is a waste. Waste of drugs during the first drugs in the stomach, the second in painkillers Coming in third and antibiotics. " A problem specific to the pharmaceutical waste is not only Turkey indicating rocks, especially in Asian countries has made the world is experiencing this hardship. Kaya, see injustice in the world of medicine is available, the least developed countries is experiencing difficulty in reaching the drugs in question added.
Depression and the pharmaceutical sector
U.S. and signs of stagnation in the world is growing steadily. American financial companies to disclose losses in a row. Yesterday the stock market in the world including the ISE has been hard to drop.
Reflected in the stock market started to slowdown of the source of uneasiness on Thursday past, cities were in Basel, Switzerland. Europe's second largest pharmaceutical company Novartis'in center here. The company is active in 140 countries worldwide and has production facilities in Turkey five. Novartis managers around the world, around 200 journalists from different countries participated in a press conference unveiled the 2007 results and future plans.
Pharmaceuticals and health sector, a vital sector, and thus is not a direct impact in the world to economic fluctuations. The highest impact on the government's "reimbursement system" that some changes in.
Pharmaceutical companies, 2007 has closed quite profitable. It is one of the most important players of the industry financial results Novartis'in it is confirmed. Group sales in 2007, some 8 percent in local currency by increasing the basis of 3 percent to $ 39.8 billion was removed. Percent increase in net income of 11.97 billion dollars 66'lık.
Biotechnological production in 2008 will concentrate on the group, will continue to open research center. Drug development speed, improve productivity and quality will matter. Emerging China, Brazil, Turkey and Korea will focus on the market. To increase speed and efficiency, to reduce costs, and this frame will go to rebuild a 100-thousand workers will split ways with 2 thousand 500.
Despite expectations of a worldwide recession, many pharmaceutical companies like Novartis, this year and hopeful future. The information provided by senior managers from Novartis'in the impression, in the coming period in this sector will experience significant development in the direction.
Novartis chairman Daniel Vasella, the company mergers in the sector will continue after that, as stated, "We just can not maintain your position in the world with organic growth. Also have to make strategic acquisitions." he says.
In fact, Novartis, 1996, Switzerland's largest chemical company with two drugs and Ciba-Geigy and was formed by coming together Sandoz'un purchase a company with growth.
Another question my attention Vasella'nın the "vaccine" on. According to him, "vaccine" in the future will have very great importance. Novartis Vaccines Division President Joerg Reinhardt says the same thing. Rather than long-term treatment to prevent the return of the health sector is going to highlight.
Double-digit sales growth two years Novartis'in vaccine. 36 per cent in 2006, 25th percent in 2007 Reinhardt, 2008 of the new vaccine will be released, but says growth will continue performance.
Probably the most important medicines of the future will be immunized. In this way, many diseases, emerging from the front. People will start after the birth will be protected by vaccination. But this does not mean that the disease will be over in their entirety. Past experience has shown that the drug is a disease is discovered, another disease show begin.
And unfortunately, vaccine development and as a very backward country produced. At this point, our research and development is poor we created. Many countries in this field we work in the billions of dollars invested in not a few.
After the meeting, Dr Novartis Global Head of Drug Development. James would like to chat Shannon'la. They want to focus on developing research in Turkey, but the scarcity of trained staff because of their desire not say speed access. There are currently a part of clinical research are in Turkey, but not yet in other areas of research.
Bird flu disease from cancer in the world many new discoveries waiting. The treatment of cancer research in particular to the property is big money. And some take a long time to research on diseases. Novartis Oncology Department, David Epstein, "the world with more than 200 different types of cancer for years, is one of struggle. For example, breast cancer five years ago was more deadly. Geliştirilen As a result of treatment today, 80 percent of patients can continue their lives." he says.
Topics can be extended, but will be summarized, no matter what drugs and treatment methods, the importance to the sector will continue to lose.
Reflected in the stock market started to slowdown of the source of uneasiness on Thursday past, cities were in Basel, Switzerland. Europe's second largest pharmaceutical company Novartis'in center here. The company is active in 140 countries worldwide and has production facilities in Turkey five. Novartis managers around the world, around 200 journalists from different countries participated in a press conference unveiled the 2007 results and future plans.
Pharmaceuticals and health sector, a vital sector, and thus is not a direct impact in the world to economic fluctuations. The highest impact on the government's "reimbursement system" that some changes in.
Pharmaceutical companies, 2007 has closed quite profitable. It is one of the most important players of the industry financial results Novartis'in it is confirmed. Group sales in 2007, some 8 percent in local currency by increasing the basis of 3 percent to $ 39.8 billion was removed. Percent increase in net income of 11.97 billion dollars 66'lık.
Biotechnological production in 2008 will concentrate on the group, will continue to open research center. Drug development speed, improve productivity and quality will matter. Emerging China, Brazil, Turkey and Korea will focus on the market. To increase speed and efficiency, to reduce costs, and this frame will go to rebuild a 100-thousand workers will split ways with 2 thousand 500.
Despite expectations of a worldwide recession, many pharmaceutical companies like Novartis, this year and hopeful future. The information provided by senior managers from Novartis'in the impression, in the coming period in this sector will experience significant development in the direction.
Novartis chairman Daniel Vasella, the company mergers in the sector will continue after that, as stated, "We just can not maintain your position in the world with organic growth. Also have to make strategic acquisitions." he says.
In fact, Novartis, 1996, Switzerland's largest chemical company with two drugs and Ciba-Geigy and was formed by coming together Sandoz'un purchase a company with growth.
Another question my attention Vasella'nın the "vaccine" on. According to him, "vaccine" in the future will have very great importance. Novartis Vaccines Division President Joerg Reinhardt says the same thing. Rather than long-term treatment to prevent the return of the health sector is going to highlight.
Double-digit sales growth two years Novartis'in vaccine. 36 per cent in 2006, 25th percent in 2007 Reinhardt, 2008 of the new vaccine will be released, but says growth will continue performance.
Probably the most important medicines of the future will be immunized. In this way, many diseases, emerging from the front. People will start after the birth will be protected by vaccination. But this does not mean that the disease will be over in their entirety. Past experience has shown that the drug is a disease is discovered, another disease show begin.
And unfortunately, vaccine development and as a very backward country produced. At this point, our research and development is poor we created. Many countries in this field we work in the billions of dollars invested in not a few.
After the meeting, Dr Novartis Global Head of Drug Development. James would like to chat Shannon'la. They want to focus on developing research in Turkey, but the scarcity of trained staff because of their desire not say speed access. There are currently a part of clinical research are in Turkey, but not yet in other areas of research.
Bird flu disease from cancer in the world many new discoveries waiting. The treatment of cancer research in particular to the property is big money. And some take a long time to research on diseases. Novartis Oncology Department, David Epstein, "the world with more than 200 different types of cancer for years, is one of struggle. For example, breast cancer five years ago was more deadly. Geliştirilen As a result of treatment today, 80 percent of patients can continue their lives." he says.
Topics can be extended, but will be summarized, no matter what drugs and treatment methods, the importance to the sector will continue to lose.
Subscribe to:
Posts (Atom)
